The	O
involvement	O
of	O
TNF-alpha	B-protein
-related	O
apoptosis-inducing	O
ligand	O
in	O
the	O
enhanced	O
cytotoxicity	O
of	O
IFN-beta	B-protein
-stimulated	O
human	B-cell_type
dendritic	I-cell_type
cells	I-cell_type
to	O
tumor	B-cell_type
cells	I-cell_type
.	O

TNF-alpha	B-protein
-related	O
apoptosis-inducing	O
ligand	O
(	O
TRAIL	O
)	O
is	O
characterized	O
by	O
its	O
preferential	O
induction	O
of	O
apoptosis	O
of	O
tumor	B-cell_type
cells	I-cell_type
but	O
not	O
normal	B-cell_type
cells	I-cell_type
.	O

Dendritic	B-cell_type
cells	I-cell_type
(	O
DCs	B-cell_type
)	O
,	O
besides	O
their	O
role	O
as	O
APCs	O
,	O
now	O
have	O
been	O
demonstrated	O
to	O
exert	O
cytotoxicity	O
or	O
cytostasis	O
on	O
some	O
tumor	B-cell_type
cells	I-cell_type
.	O

Here	O
,	O
we	O
report	O
that	O
both	O
human	B-cell_type
CD34	I-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
stem	I-cell_type
cell	I-cell_type
-derived	O
DCs	B-cell_type
(	O
CD34DCs	B-cell_type
)	O
and	O
human	B-cell_type
CD14	I-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
monocyte	I-cell_type
-derived	O
DCs	B-cell_type
(	O
MoDCs	B-cell_type
)	O
express	O
TRAIL	O
and	O
exhibit	O
cytotoxicity	O
to	O
some	O
types	O
of	O
tumor	B-cell_type
cells	I-cell_type
partially	O
through	O
TRAIL	O
.	O

Moderate	O
expression	O
of	O
TRAIL	O
appeared	O
on	O
CD34DCs	B-cell_type
from	O
the	O
8th	O
day	O
of	O
culture	O
and	O
was	O
also	O
seen	O
on	O
freshly	B-cell_type
isolated	I-cell_type
monocytes	I-cell_type
.	O

The	O
level	O
of	O
TRAIL	O
expression	O
remained	O
constant	O
until	O
DC	O
maturation	O
.	O

TRAIL	O
expression	O
on	O
immature	B-cell_type
CD34DCs	I-cell_type
or	O
MoDCs	B-cell_type
was	O
greatly	O
up-regulated	O
after	O
IFN-beta	B-protein
stimulation	O
.	O

Moreover	O
,	O
IFN-beta	B-protein
could	O
strikingly	O
enhance	O
the	O
ability	O
of	O
CD34DCs	B-cell_type
or	O
MoDCs	B-cell_type
to	O
kill	O
TRAIL-sensitive	O
tumor	B-cell_type
cells	I-cell_type
,	O
but	O
LPS	O
did	O
not	O
have	O
such	O
an	O
effect	O
.	O

The	O
up-regulation	O
of	O
TRAIL	O
on	O
IFN-beta	B-protein
-stimulated	O
DCs	B-cell_type
partially	O
contributed	O
to	O
the	O
increased	O
cytotoxicity	O
of	O
DCS	B-cell_type
:	O
Pretreatment	O
of	O
TRAIL-sensitive	O
tumor	B-cell_type
cells	I-cell_type
with	O
caspase-3	O
inhibitor	O
could	O
significantly	O
increase	O
their	O
resistance	O
to	O
the	O
cytotoxicity	O
of	O
IFN-beta	B-protein
-stimulated	O
DCS	B-cell_type
:	O
In	O
contrast	O
,	O
NF-kappaB	O
inhibitor	O
could	O
significantly	O
increase	O
the	O
sensitivity	O
of	O
tumor	B-cell_type
cells	I-cell_type
to	O
the	O
killing	O
by	O
nonstimulated	O
or	O
LPS-stimulated	O
DCS	B-cell_type
:	O
Our	O
studies	O
demonstrate	O
that	O
IFN-beta	B-protein
-stimulated	O
DCs	B-cell_type
are	O
functionally	O
cytotoxic	O
.	O

Thus	O
,	O
an	O
innate	O
mechanism	O
of	O
DC-mediated	O
antitumor	O
immunity	O
might	O
exist	O
in	O
vivo	O
in	O
which	O
DCs	B-cell_type
act	O
as	O
effectors	O
to	O
directly	O
kill	O
tumor	B-cell_type
cells	I-cell_type
partially	O
via	O
TRAIL	O
.	O

Subsequently	O
,	O
DCs	B-cell_type
act	O
as	O
APCs	O
involved	O
in	O
the	O
uptake	O
,	O
processing	O
,	O
and	O
presentation	O
of	O
apoptotic	B-protein
tumor	I-protein
Ags	I-protein
to	O
cross-prime	O
CD8	B-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
CTL	I-cell_type
cells	I-cell_type
.	O

'_9	NULL
Analytes	NULL
=	NULL
Comprehensive	NULL
Analysis	NULL
n	NULL
MICFOVUG	NULL
Wim	NULL
Ba	NULL
,	NULL
Bb	NULL
,	NULL
C3a	NULL
,	NULL
C4a	NULL
,	NULL
C4d	NULL
,	NULL
CSa	NULL
,	NULL
s	NULL
SCS5b-9	NULL
,	NULL
Factor	NULL
H	NULL
,	NULL
Factor	NULL
|	NULL
QUIpEL	NULL
MULTIPLEX	NULL
I	NULL
ill	NULL
``	NULL
``	NULL
A	NULL
SE	NULL
ty	NULL
ay	NULL
Ail	NULL
me	NULL
Journal	NULL
o	NULL
The	NULL
Involvement	NULL
of	NULL
BD	NULL
tinmunol	NULL
Apoptosis-Inducing	NULL
Ligand	NULL
in	NULL
the	NULL
Enhanced	NULL
unotogy	NULL
Cytotoxicity	NULL
of	NULL
IFN-B-Stimulated	NULL
Human	NULL
Dendritic	NULL
Cells	NULL
to	NULL
Tumor	NULL
Cells	NULL
This	NULL
information	NULL
is	NULL
current	NULL
as	NULL
of	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

Shuxun	NULL
Liu	NULL
,	NULL
Yizhi	NULL
Yu	NULL
,	NULL
Minghui	NULL
Zhang	NULL
,	NULL
Wenya	NULL
Wang	NULL
and	NULL
Xuetao	NULL
Cao	NULL
J	NULL
Immunol	NULL
2001	NULL
;	NULL
166:5407-5415	NULL
;	NULL
;	NULL
doi	NULL
:	NULL
10.4049/jimmunol.166.9.5407	NULL
http	NULL
:	NULL
//www	NULL
.jimmunol.org/content/166/9/5407	NULL
\ge	NULL
?	NULL

u	NULL
References	NULL
_	NULL
This	NULL
article	NULL
cites	NULL
48	NULL
articles	NULL
,	NULL
30	NULL
of	NULL
which	NULL
you	NULL
can	NULL
access	NULL
for	NULL
free	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//www	NULL
.jimmunol.org/content/166/9/5407	NULL
.	NULL

full	NULL
#	NULL
ref-list-1	NULL
Why	NULL
The	NULL
JT	NULL
?	NULL

Submit	NULL
online	NULL
.	NULL

«	NULL
Rapid	NULL
Reviews	NULL
!	NULL

30	NULL
days*	NULL
from	NULL
submission	NULL
to	NULL
initial	NULL
decision	NULL
*	NULL
No	NULL
Triage	NULL
!	NULL

Every	NULL
submission	NULL
reviewed	NULL
by	NULL
practicing	NULL
scientists	NULL
*	NULL
Fast	NULL
Publication	NULL
!	NULL

4	NULL
weeks	NULL
from	NULL
acceptance	NULL
to	NULL
publication	NULL
*average	NULL
Subscription	NULL
_-	NULL
Information	NULL
about	NULL
subscribing	NULL
to	NULL
The	NULL
Journal	NULL
of	NULL
Immunology	NULL
is	NULL
online	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//jimmunol.org/subscription	NULL
Permissions	NULL
_	NULL
Submit	NULL
copyright	NULL
permission	NULL
requests	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//www.aai.org/About/Publications/Jl/copyright.html	NULL
Email	NULL
Alerts	NULL
_	NULL
Receive	NULL
free	NULL
email-alerts	NULL
when	NULL
new	NULL
articles	NULL
cite	NULL
this	NULL
article	NULL
.	NULL

Sign	NULL
up	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//jimmunol.org/alerts	NULL
The	NULL
Journal	NULL
of	NULL
Immunology	NULL
is	NULL
published	NULL
twice	NULL
each	NULL
month	NULL
by	NULL
The	NULL
American	NULL
Association	NULL
of	NULL
Immunologists	NULL
,	NULL
Inc.	NULL
,	NULL
1451	NULL
Rockville	NULL
Pike	NULL
,	NULL
Suite	NULL
650	NULL
,	NULL
Rockville	NULL
,	NULL
MD	NULL
20852	NULL
Copyright	NULL
©	NULL
2001	NULL
by	NULL
The	NULL
American	NULL
Association	NULL
of	NULL
Immunologists	NULL
All	NULL
rights	NULL
reserved	NULL
.	NULL

Print	NULL
ISSN	NULL
:	NULL
0022-1767	NULL
Online	NULL
ISSN	NULL
:	NULL
1550-6606	NULL
.	NULL

6107	NULL
'0t	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
[	NULL
810	NULL
fountwrut	NULL
[	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
The	NULL
Involvement	NULL
of	NULL
TNF-a-Related	NULL
Apoptosis-Inducing	NULL
Ligand	NULL
in	NULL
the	NULL
Enhanced	NULL
Cytotoxicity	NULL
of	NULL
IFN-B-Stimulated	NULL
Human	NULL
Dendritic	NULL
Cells	NULL
to	NULL
Tumor	NULL
Cells	NULL
!	NULL

Shuxun	NULL
Liu	NULL
,	NULL
Yizhi	NULL
Yu	NULL
,	NULL
Minghui	NULL
Zhang	NULL
,	NULL
Wenya	NULL
Wang	NULL
,	NULL
and	NULL
Xuetao	NULL
Cao	NULL
TNF-a-related	NULL
apoptosis-inducing	NULL
ligand	NULL
(	NULL
TRAIL	NULL
)	NULL
is	NULL
characterized	NULL
by	NULL
its	NULL
preferential	NULL
induction	NULL
of	NULL
apoptosis	NULL
of	NULL
tumor	NULL
cells	NULL
but	NULL
not	NULL
normal	NULL
cells	NULL
.	NULL

Dendritic	NULL
cells	NULL
(	NULL
DCs	NULL
)	NULL
,	NULL
besides	NULL
their	NULL
role	NULL
as	NULL
APCs	NULL
,	NULL
now	NULL
have	NULL
been	NULL
demonstrated	NULL
to	NULL
exert	NULL
cytotoxicity	NULL
or	NULL
cytostasis	NULL
on	NULL
some	NULL
tumor	NULL
cells	NULL
.	NULL

Here	NULL
,	NULL
we	NULL
report	NULL
that	NULL
both	NULL
human	NULL
CD34*	NULL
stem	NULL
cell-derived	NULL
DCs	NULL
(	NULL
CD34DCs	NULL
)	NULL
and	NULL
human	NULL
CD14*	NULL
monocyte-derived	NULL
DCs	NULL
(	NULL
MoDCs	NULL
)	NULL
express	NULL
TRAIL	NULL
and	NULL
exhibit	NULL
cytotoxicity	NULL
to	NULL
some	NULL
types	NULL
of	NULL
tumor	NULL
cells	NULL
partially	NULL
through	NULL
TRAIL	NULL
.	NULL

Moderate	NULL
expression	NULL
of	NULL
TRAIL	NULL
appeared	NULL
on	NULL
CD3MADCs	NULL
from	NULL
the	NULL
8th	NULL
day	NULL
of	NULL
culture	NULL
and	NULL
was	NULL
also	NULL
seen	NULL
on	NULL
freshly	NULL
isolated	NULL
monocytes	NULL
.	NULL

The	NULL
level	NULL
of	NULL
TRAIL	NULL
expression	NULL
remained	NULL
constant	NULL
until	NULL
DC	NULL
maturation	NULL
.	NULL

TRAIL	NULL
expression	NULL
on	NULL
immature	NULL
CD34DCs	NULL
or	NULL
MoDCs	NULL
was	NULL
greatly	NULL
up-regulated	NULL
after	NULL
IFN-	NULL
stimulation	NULL
.	NULL

Moreover	NULL
,	NULL
IFN-	NULL
could	NULL
strikingly	NULL
enhance	NULL
the	NULL
ability	NULL
of	NULL
CD34DCs	NULL
or	NULL
MoDCs	NULL
to	NULL
kill	NULL
TRAIL-sensitive	NULL
tumor	NULL
cells	NULL
,	NULL
but	NULL
LPS	NULL
did	NULL
not	NULL
have	NULL
such	NULL
an	NULL
effect	NULL
.	NULL

The	NULL
up-regulation	NULL
of	NULL
TRAIL	NULL
on	NULL
IFN	NULL
--	NULL
stimulated	NULL
DCs	NULL
partially	NULL
contributed	NULL
to	NULL
the	NULL
increased	NULL
cytotoxicity	NULL
of	NULL
DCs	NULL
.	NULL

Pretreatment	NULL
of	NULL
TRAIL-sensitive	NULL
tumor	NULL
cells	NULL
with	NULL
caspase-3	NULL
inhibitor	NULL
could	NULL
significantly	NULL
increase	NULL
their	NULL
resistance	NULL
to	NULL
the	NULL
cytotoxicity	NULL
of	NULL
IFN-	NULL
$	NULL
-stimulated	NULL
DCs	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
NF-KB	NULL
inhibitor	NULL
could	NULL
significantly	NULL
increase	NULL
the	NULL
sensitivity	NULL
of	NULL
tumor	NULL
cells	NULL
to	NULL
the	NULL
killing	NULL
by	NULL
nonstimulated	NULL
or	NULL
LPS-stimulated	NULL
DCs	NULL
.	NULL

Our	NULL
studies	NULL
demonstrate	NULL
that	NULL
IFN	NULL
--	NULL
stimulated	NULL
DCs	NULL
are	NULL
functionally	NULL
cytotoxic	NULL
.	NULL

Thus	NULL
,	NULL
an	NULL
innate	NULL
mechanism	NULL
of	NULL
DC-mediated	NULL
antitumor	NULL
immunity	NULL
might	NULL
exist	NULL
in	NULL
vivo	NULL
in	NULL
which	NULL
DCs	NULL
act	NULL
as	NULL
effectors	NULL
to	NULL
directly	NULL
kill	NULL
tumor	NULL
cells	NULL
partially	NULL
via	NULL
TRAIL	NULL
.	NULL

Subsequently	NULL
,	NULL
DCs	NULL
act	NULL
as	NULL
APCs	NULL
involved	NULL
in	NULL
the	NULL
uptake	NULL
,	NULL
processing	NULL
,	NULL
and	NULL
presentation	NULL
of	NULL
apoptotic	NULL
tumor	NULL
Ags	NULL
to	NULL
cross-prime	NULL
CD8*	NULL
CTL	NULL
cells	NULL
.	NULL

The	NULL
Journal	NULL
of	NULL
Immunology	NULL
,	NULL
2001	NULL
,	NULL
166	NULL
:	NULL
5407-5415.	NULL
endritic	NULL
cells	NULL
(	NULL
DCs	NULL
)	NULL
,	NULL
``	NULL
as	NULL
highly	NULL
specialized	NULL
Ag	NULL
APCs	NULL
,	NULL
are	NULL
D	NULL
responsible	NULL
for	NULL
the	NULL
induction	NULL
of	NULL
primary	NULL
immune	NULL
responses	NULL
(	NULL
1	NULL
)	NULL
.	NULL

DCs	NULL
play	NULL
critical	NULL
roles	NULL
in	NULL
antitumor	NULL
or	NULL
an-tivirus	NULL
immune	NULL
responses	NULL
,	NULL
autoimmune	NULL
diseases	NULL
,	NULL
and	NULL
graft	NULL
rejec-tion	NULL
.	NULL

The	NULL
participation	NULL
of	NULL
CD8	NULL
*	NULL
CTL	NULL
cells	NULL
that	NULL
are	NULL
induced	NULL
by	NULL
cross-priming	NULL
by	NULL
DCs	NULL
is	NULL
considered	NULL
a	NULL
major	NULL
mechanism	NULL
involved	NULL
in	NULL
such	NULL
immune	NULL
responses	NULL
.	NULL

Exogenous	NULL
antigenic	NULL
peptides	NULL
are	NULL
cross-presented	NULL
by	NULL
DCs	NULL
to	NULL
T	NULL
cells	NULL
in	NULL
the	NULL
form	NULL
of	NULL
peptide-MHC	NULL
class	NULL
I	NULL
complexes	NULL
,	NULL
thus	NULL
stimulating	NULL
Ag-specific	NULL
CTL	NULL
responses	NULL
.	NULL

The	NULL
induction	NULL
of	NULL
specific	NULL
CD8	NULL
*	NULL
CTL	NULL
is	NULL
a	NULL
major	NULL
possibility	NULL
in	NULL
the	NULL
treatment	NULL
of	NULL
cancer	NULL
(	NULL
2-4	NULL
)	NULL
.	NULL

To	NULL
date	NULL
,	NULL
DC-based	NULL
tumor	NULL
vaccinations	NULL
in	NULL
the	NULL
treatment	NULL
of	NULL
cancer	NULL
patients	NULL
have	NULL
shown	NULL
promising	NULL
results	NULL
from	NULL
clinical	NULL
trials	NULL
(	NULL
5-8	NULL
)	NULL
.	NULL

Apoptotic	NULL
tumor	NULL
cells	NULL
are	NULL
considered	NULL
more	NULL
effective	NULL
than	NULL
tumor	NULL
debris	NULL
or	NULL
tumor	NULL
cells	NULL
alone	NULL
at	NULL
supplying	NULL
host	NULL
DCs	NULL
with	NULL
a	NULL
source	NULL
of	NULL
antigenic	NULL
epitopes	NULL
for	NULL
cross-priming	NULL
autologous	NULL
CD8	NULL
*	NULL
CTLs	NULL
(	NULL
9	NULL
,	NULL
10	NULL
)	NULL
.	NULL

Bystander	NULL
apoptotic	NULL
cells	NULL
are	NULL
able	NULL
to	NULL
trigger	NULL
DC	NULL
maturation	NULL
to	NULL
Ag	NULL
presentation	NULL
function	NULL
even	NULL
without	NULL
Department	NULL
of	NULL
Immunology	NULL
,	NULL
Second	NULL
Military	NULL
Medical	NULL
University	NULL
,	NULL
Shanghei	NULL
,	NULL
People	NULL
's	NULL
Republic	NULL
of	NULL
China	NULL
Received	NULL
for	NULL
publication	NULL
August	NULL
11	NULL
,	NULL
2000	NULL
.	NULL

Accepted	NULL
for	NULL
publication	NULL
February	NULL
21	NULL
,	NULL
2001	NULL
.	NULL

The	NULL
costs	NULL
of	NULL
publication	NULL
of	NULL
this	NULL
article	NULL
were	NULL
defrayed	NULL
in	NULL
part	NULL
by	NULL
the	NULL
payment	NULL
of	NULL
page	NULL
charges	NULL
.	NULL

This	NULL
article	NULL
must	NULL
therefore	NULL
be	NULL
hereby	NULL
marked	NULL
adverfisement	NULL
in	NULL
accordance	NULL
with	NULL
18	NULL
U.S.C	NULL
.	NULL

Section	NULL
1734	NULL
solely	NULL
to	NULL
indicate	NULL
this	NULL
fact	NULL
.	NULL
'	NULL

This	NULL
work	NULL
was	NULL
supported	NULL
by	NULL
Grants	NULL
39825123	NULL
and	NULL
39730420	NULL
from	NULL
the	NULL
National	NULL
Natural	NULL
Science	NULL
Foundation	NULL
of	NULL
China	NULL
.	NULL

?	NULL

Address	NULL
correspondence	NULL
and	NULL
reprint	NULL
requests	NULL
to	NULL
Dr.	NULL
Xuctao	NULL
Cao	NULL
,	NULL
Department	NULL
of	NULL
Immunology	NULL
,	NULL
Second	NULL
Military	NULL
Medical	NULL
University	NULL
,	NULL
800	NULL
Xiangyin	NULL
Road	NULL
,	NULL
Shanghai	NULL
200433	NULL
,	NULL
People	NULL
's	NULL
Republic	NULL
of	NULL
China	NULL
.	NULL

3	NULL
Abbreviations	NULL
used	NULL
in	NULL
this	NULL
paper	NULL
:	NULL
DC	NULL
,	NULL
dendritic	NULL
cell	NULL
;	NULL
TRAIL	NULL
,	NULL
TNF-a-related	NULL
apoptosis-inducing	NULL
ligand	NULL
;	NULL
MoDC	NULL
,	NULL
monocyte-derived	NULL
DC	NULL
;	NULL
FADD	NULL
,	NULL
Fas-associated	NULL
death	NULL
domain-containging	NULL
protein	NULL
;	NULL
c-FLIP	NULL
,	NULL
cellular	NULL
FADD-like	NULL
IL-1	NULL
converting	NULL
enzyme	NULL
protease-inhibitory	NULL
protein	NULL
;	NULL
CD34DC	NULL
,	NULL
human	NULL
CD34	NULL
*	NULL
stem	NULL
cell-drived	NULL
DCs	NULL
;	NULL
CD95L	NULL
,	NULL
C95	NULL
ligand	NULL
.	NULL

Copyright	NULL
©	NULL
2001	NULL
by	NULL
The	NULL
American	NULL
Association	NULL
of	NULL
Immunologists	NULL
exogenous	NULL
``	NULL
danger	NULL
``	NULL
signals	NULL
(	NULL
11	NULL
)	NULL
.	NULL

In	NULL
the	NULL
capturing	NULL
of	NULL
Ags	NULL
,	NULL
the	NULL
«	NULL
,	NULL
f	NULL
,	NULL
and	NULL
CD36	NULL
molecules	NULL
on	NULL
DCs	NULL
possibly	NULL
mediate	NULL
phagocytosis	NULL
of	NULL
apoptotic	NULL
cells	NULL
;	NULL
whereas	NULL
in	NULL
processing	NULL
and	NULL
presentation	NULL
,	NULL
heat	NULL
shock	NULL
protein	NULL
70	NULL
and	NULL
other	NULL
maturation	NULL
factors	NULL
released	NULL
from	NULL
apoptotic	NULL
cells	NULL
are	NULL
likely	NULL
to	NULL
help	NULL
induction	NULL
of	NULL
DC	NULL
maturation	NULL
and	NULL
direct	NULL
antigenic	NULL
peptides	NULL
for	NULL
MHC	NULL
class	NULL
I	NULL
presentation	NULL
(	NULL
12	NULL
,	NULL
13	NULL
)	NULL
.	NULL

Optimal	NULL
cross-priming	NULL
of	NULL
CD8	NULL
*	NULL
CTLs	NULL
by	NULL
DC	NULL
's	NULL
requires	NULL
both	NULL
apoptotic	NULL
bodies	NULL
for	NULL
Ags	NULL
and	NULL
necrotic	NULL
cells	NULL
for	NULL
delivering	NULL
maturation	NULL
signals	NULL
(	NULL
14	NULL
)	NULL
.	NULL

Nevertheless	NULL
,	NULL
a	NULL
critical	NULL
prerequisite	NULL
is	NULL
the	NULL
existence	NULL
of	NULL
apoptotic	NULL
bodies	NULL
,	NULL
but	NULL
little	NULL
is	NULL
known	NULL
about	NULL
their	NULL
origin	NULL
.	NULL

Innate	NULL
defense	NULL
mechanisms	NULL
are	NULL
comprised	NULL
of	NULL
macrophages	NULL
,	NULL
NK	NULL
cells	NULL
,	NULL
comple-ment	NULL
,	NULL
and	NULL
interferons	NULL
,	NULL
which	NULL
can	NULL
directly	NULL
delete	NULL
pathogens	NULL
or	NULL
unwanted	NULL
cells	NULL
.	NULL

Although	NULL
it	NULL
is	NULL
well	NULL
known	NULL
that	NULL
DCs	NULL
are	NULL
widely	NULL
distributed	NULL
in	NULL
peripheral	NULL
tissues	NULL
,	NULL
are	NULL
important	NULL
as	NULL
a	NULL
first	NULL
line	NULL
of	NULL
defense	NULL
,	NULL
and	NULL
make	NULL
regular	NULL
encounters	NULL
with	NULL
tumor	NULL
cells	NULL
,	NULL
there	NULL
is	NULL
no	NULL
evidence	NULL
that	NULL
DCs	NULL
also	NULL
belong	NULL
to	NULL
the	NULL
natural	NULL
defense	NULL
arm	NULL
of	NULL
the	NULL
immune	NULL
response	NULL
,	NULL
directly	NULL
eliminating	NULL
deleterious	NULL
factors	NULL
.	NULL

Some	NULL
reports	NULL
suggest	NULL
that	NULL
DCs	NULL
may	NULL
have	NULL
a	NULL
direct	NULL
role	NULL
in	NULL
the	NULL
elimination	NULL
of	NULL
malignant	NULL
cells	NULL
.	NULL

In	NULL
murine	NULL
tumor	NULL
models	NULL
,	NULL
injection	NULL
of	NULL
DCs	NULL
can	NULL
inhibit	NULL
growth	NULL
of	NULL
tumors	NULL
to	NULL
some	NULL
degree	NULL
(	NULL
15	NULL
,	NULL
16	NULL
)	NULL
.	NULL

In	NULL
rats	NULL
,	NULL
NKR-P1*	NULL
spleen	NULL
DCs	NULL
possess	NULL
cytotoxic	NULL
activity	NULL
toward	NULL
NK-sensitive	NULL
YAC-1	NULL
cells	NULL
(	NULL
17	NULL
)	NULL
.	NULL

In	NULL
humans	NULL
,	NULL
activated	NULL
DCs	NULL
appear	NULL
to	NULL
suppress	NULL
growth	NULL
of	NULL
a	NULL
variety	NULL
spectrum	NULL
of	NULL
tumor	NULL
cell	NULL
lines	NULL
in	NULL
vitro	NULL
(	NULL
18	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
Fanger	NULL
et	NULL
al	NULL
.	NULL

(	NULL
19	NULL
)	NULL
have	NULL
shown	NULL
that	NULL
a	NULL
peripheral	NULL
blood	NULL
subset	NULL
of	NULL
CD11c*	NULL
DCs	NULL
,	NULL
but	NULL
not	NULL
IL-3Ra*	NULL
pre-DC	NULL
's	NULL
,	NULL
stimulated	NULL
by	NULL
IFN-y	NULL
or	NULL
IFN-a	NULL
@	NULL
can	NULL
induce	NULL
cellular	NULL
apoptosis	NULL
in	NULL
several	NULL
tumor	NULL
cells	NULL
.	NULL

Recently	NULL
,	NULL
numerous	NULL
apoptosis-inducing	NULL
ligands	NULL
have	NULL
been	NULL
dis-covered	NULL
,	NULL
most	NULL
of	NULL
them	NULL
belonging	NULL
to	NULL
the	NULL
TNF	NULL
family	NULL
(	NULL
20-24	NULL
)	NULL
TNE-a-related	NULL
apoptosis-inducing	NULL
ligand	NULL
(	NULL
TRAIL	NULL
)	NULL
,	NULL
a	NULL
newly	NULL
discovered	NULL
member	NULL
of	NULL
the	NULL
TNF	NULL
family	NULL
,	NULL
together	NULL
with	NULL
€D95	NULL
ligand	NULL
(	NULL
CD95L	NULL
)	NULL
and	NULL
TNF-	NULL
«	NULL
,	NULL
belongs	NULL
to	NULL
subgroup	NULL
of	NULL
apoptosis-inducing	NULL
ligands	NULL
(	NULL
25-27	NULL
)	NULL
.	NULL

The	NULL
corresponding	NULL
death	NULL
receptors	NULL
are	NULL
members	NULL
of	NULL
the	NULL
0022-1767/01/	NULL
$	NULL
02.00	NULL
6107	NULL
'0t	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
[	NULL
810	NULL
fountwrut	NULL
[	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
5408	NULL
CYTOTOXICITY	NULL
OF	NULL
IFN-B-STIMULATED	NULL
HUMAN	NULL
DC	NULL
TO	NULL
TUMOR	NULL
CELLS	NULL
TNFR	NULL
family	NULL
,	NULL
the	NULL
cytoplasmic	NULL
regions	NULL
of	NULL
which	NULL
all	NULL
contain	NULL
a	NULL
crucial	NULL
domain	NULL
for	NULL
mediating	NULL
apoptotic	NULL
signals	NULL
,	NULL
called	NULL
the	NULL
death	NULL
domain	NULL
.	NULL

Upon	NULL
the	NULL
oligomerization	NULL
of	NULL
these	NULL
receptors	NULL
triggered	NULL
by	NULL
their	NULL
ligands	NULL
on	NULL
the	NULL
surface	NULL
,	NULL
the	NULL
death	NULL
domains	NULL
can	NULL
recruit	NULL
intracellular	NULL
signal	NULL
molecules	NULL
,	NULL
such	NULL
as	NULL
Fas-associated	NULL
death	NULL
domain-containing	NULL
protein	NULL
(	NULL
FADD	NULL
)	NULL
,	NULL
which	NULL
can	NULL
activate	NULL
downstream	NULL
caspase	NULL
cascades	NULL
leading	NULL
to	NULL
a	NULL
series	NULL
of	NULL
apoptotic	NULL
events	NULL
(	NULL
28	NULL
)	NULL
.	NULL

Unlike	NULL
CD95L	NULL
and	NULL
TNF-a	NULL
,	NULL
TRAIL	NULL
was	NULL
characterized	NULL
by	NULL
selective	NULL
induction	NULL
of	NULL
apoptotic	NULL
cell	NULL
death	NULL
in	NULL
a	NULL
variety	NULL
of	NULL
tumor	NULL
cells	NULL
or	NULL
transformed	NULL
cells	NULL
,	NULL
but	NULL
not	NULL
in	NULL
normal	NULL
cells	NULL
.	NULL

The	NULL
TRAIL-resistant	NULL
property	NULL
of	NULL
normal	NULL
cells	NULL
and	NULL
some	NULL
tumor	NULL
cells	NULL
may	NULL
be	NULL
due	NULL
to	NULL
the	NULL
expression	NULL
of	NULL
its	NULL
two	NULL
decoy	NULL
receptors	NULL
and	NULL
some	NULL
intracellularly	NULL
resistant	NULL
molecules	NULL
,	NULL
such	NULL
as	NULL
cellular	NULL
FADD-like	NULL
IL-1B-converting	NULL
enzyme	NULL
protease-inhibitory	NULL
protein	NULL
(	NULL
c-FLIP	NULL
)	NULL
;	NULL
and	NULL
to	NULL
the	NULL
activation	NULL
of	NULL
antiapoptotic	NULL
mechanisms	NULL
,	NULL
e.g	NULL
.	NULL

,	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
(	NULL
29-36	NULL
)	NULL
.	NULL

TRAIL	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
participate	NULL
in	NULL
the	NULL
tumoricidal	NULL
activity	NULL
of	NULL
CD4	NULL
*	NULL
T	NULL
cells	NULL
,	NULL
NK	NULL
cells	NULL
,	NULL
monocytes	NULL
,	NULL
and	NULL
DCs	NULL
under	NULL
certain	NULL
conditions	NULL
(	NULL
19	NULL
,	NULL
26	NULL
,	NULL
37	NULL
,	NULL
38	NULL
)	NULL
.	NULL

However	NULL
,	NULL
there	NULL
have	NULL
been	NULL
no	NULL
reports	NULL
concerning	NULL
the	NULL
killing	NULL
of	NULL
tumor	NULL
cells	NULL
by	NULL
in	NULL
vitro	NULL
cultured	NULL
human	NULL
CD34*	NULL
stem	NULL
cell-derived	NULL
DCs	NULL
(	NULL
CD34DCs	NULL
)	NULL
and	NULL
human	NULL
CD14*	NULL
monocyte-derived	NULL
DCs	NULL
(	NULL
MoDCs	NULL
)	NULL
via	NULL
TRAIL	NULL
.	NULL

The	NULL
major	NULL
aim	NULL
of	NULL
this	NULL
study	NULL
was	NULL
to	NULL
investigate	NULL
whether	NULL
human	NULL
CD34DCs	NULL
and	NULL
MoDCs	NULL
cultured	NULL
in	NULL
vitro	NULL
are	NULL
able	NULL
to	NULL
kill	NULL
TRAIL-sensitive	NULL
tumor	NULL
cells	NULL
via	NULL
TRAIL	NULL
and	NULL
to	NULL
dissect	NULL
relevant	NULL
intracellular	NULL
mechanisms	NULL
.	NULL

Our	NULL
studies	NULL
revealed	NULL
that	NULL
IFN-	NULL
could	NULL
enhance	NULL
the	NULL
cytotoxicity	NULL
of	NULL
CD34DCs	NULL
or	NULL
MoDCs	NULL
to	NULL
TRAIL-sensitive	NULL
tumor	NULL
cells	NULL
,	NULL
which	NULL
was	NULL
partially	NULL
related	NULL
to	NULL
the	NULL
up-regulation	NULL
of	NULL
TRAIL	NULL
expression	NULL
.	NULL

However	NULL
,	NULL
a	NULL
maturation	NULL
factor	NULL
,	NULL
LPS	NULL
,	NULL
did	NULL
not	NULL
have	NULL
such	NULL
an	NULL
effect	NULL
.	NULL

The	NULL
cytotoxicity	NULL
of	NULL
DCs	NULL
toward	NULL
tumor	NULL
cells	NULL
was	NULL
regulated	NULL
by	NULL
activation	NULL
of	NULL
both	NULL
the	NULL
caspase	NULL
cascade	NULL
and	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
pathway	NULL
in	NULL
tumor	NULL
cells	NULL
.	NULL

The	NULL
physiological	NULL
and	NULL
pathological	NULL
significance	NULL
of	NULL
the	NULL
phenomenon	NULL
is	NULL
discussed	NULL
.	NULL

Materials	NULL
and	NULL
Methods	NULL
Reagents	NULL
Human	NULL
recombinant	NULL
GM-CSF	NULL
,	NULL
IL-4	NULL
,	NULL
TNF-	NULL
«	NULL
,	NULL
IFN-	NULL
,	NULL
and	NULL
the	NULL
fusion	NULL
protein	NULL
of	NULL
the	NULL
extracellular	NULL
region	NULL
of	NULL
TRAIL-R3	NULL
and	NULL
the	NULL
constant	NULL
region	NULL
of	NULL
human	NULL
IgG1	NULL
were	NULL
obtained	NULL
from	NULL
R	NULL
&	NULL
D	NULL
Systems	NULL
(	NULL
Minneapolis	NULL
,	NULL
MN	NULL
)	NULL
.	NULL

TRAIL	NULL
and	NULL
TRAIL	NULL
enhancer	NULL
were	NULL
purchased	NULL
from	NULL
Alexis	NULL
(	NULL
San	NULL
Diego	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

Human	NULL
IgG1	NULL
protein	NULL
was	NULL
from	NULL
Biodesign	NULL
International	NULL
(	NULL
Saco	NULL
,	NULL
ME	NULL
)	NULL
.	NULL

LPS	NULL
,	NULL
NF-	NULL
«	NULL
B	NULL
inhibitor	NULL
(	NULL
pyrrolidinedithiocarbamate	NULL
)	NULL
,	NULL
propidium	NULL
iodide	NULL
,	NULL
and	NULL
MTT	NULL
were	NULL
obtained	NULL
from	NULL
Sigma	NULL
(	NULL
St.	NULL
Louis	NULL
,	NULL
MO	NULL
)	NULL
.	NULL

Caspase-3	NULL
inhibitor	NULL
(	NULL
N-benzyloxy-carbonyl-Asp-Glu-Val-Asp-fluromethyl	NULL
ketone	NULL
)	NULL
was	NULL
purchased	NULL
from	NULL
Cal-biochem	NULL
(	NULL
San	NULL
Diego	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

The	NULL
reagents	NULL
mentioned	NULL
above	NULL
were	NULL
dissolved	NULL
with	NULL
serum-free	NULL
RPMI	NULL
1640	NULL
(	NULL
Life	NULL
Technologies	NULL
,	NULL
Gaithersburg	NULL
,	NULL
MD	NULL
)	NULL
to	NULL
10X	NULL
working	NULL
concentration	NULL
,	NULL
aliquoted	NULL
,	NULL
and	NULL
stored	NULL
at	NULL
-20°C	NULL
or	NULL
-80°C	NULL
.	NULL

Before	NULL
use	NULL
,	NULL
cytokines	NULL
and	NULL
other	NULL
agents	NULL
were	NULL
diluted	NULL
with	NULL
fresh	NULL
complete	NULL
medium	NULL
to	NULL
working	NULL
concentrations	NULL
.	NULL

FITC-	NULL
or	NULL
PE-Abs	NULL
mouse	NULL
anti-human	NULL
CD40	NULL
,	NULL
CD86	NULL
,	NULL
CD83	NULL
,	NULL
HLA-DR	NULL
,	NULL
CD14	NULL
,	NULL
and	NULL
isotype	NULL
control	NULL
Abs	NULL
;	NULL
mouse	NULL
anti-human	NULL
TRAIL	NULL
mAb	NULL
(	NULL
IgG2b	NULL
)	NULL
,	NULL
mouse	NULL
IgG2b	NULL
and	NULL
FITC-secondary	NULL
Ab	NULL
were	NULL
obtained	NULL
from	NULL
PharMingen	NULL
(	NULL
San	NULL
Diego	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

Goat	NULL
anti-human	NULL
polyclonal	NULL
Ab	NULL
against	NULL
caspase-3	NULL
p20	NULL
or	NULL
caspase-8	NULL
p20	NULL
,	NULL
and	NULL
donkey	NULL
anti-goat	NULL
HRP-conjugated	NULL
secondary	NULL
Ab	NULL
were	NULL
obtained	NULL
from	NULL
Santa	NULL
Cruz	NULL
Biotechnology	NULL
(	NULL
Santa	NULL
Cruz	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

Cell	NULL
lines	NULL
The	NULL
following	NULL
human	NULL
tumor	NULL
cell	NULL
lines	NULL
were	NULL
obtained	NULL
from	NULL
American	NULL
Type	NULL
Culture	NULL
Collection	NULL
(	NULL
ATCC	NULL
;	NULL
Manassas	NULL
,	NULL
VA	NULL
)	NULL
:	NULL
HL60	NULL
(	NULL
promyelocytic	NULL
leukemia	NULL
,	NULL
ATCC	NULL
CCL	NULL
240	NULL
)	NULL
;	NULL
U937	NULL
(	NULL
histiocytic	NULL
lymphoma	NULL
,	NULL
ATCC	NULL
CRL	NULL
1593	NULL
)	NULL
;	NULL
Daudi	NULL
(	NULL
Burkitt	NULL
's	NULL
lymphoma	NULL
,	NULL
ATCC	NULL
CRL	NULL
213	NULL
)	NULL
;	NULL
Jurkat	NULL
(	NULL
acute	NULL
T	NULL
cell	NULL
leukemia	NULL
,	NULL
ATCC	NULL
TIB	NULL
152	NULL
)	NULL
;	NULL
Reh	NULL
(	NULL
acute	NULL
B	NULL
cell	NULL
leukemia	NULL
,	NULL
ATCC	NULL
CRL-8283	NULL
)	NULL
.	NULL

These	NULL
cell	NULL
lines	NULL
were	NULL
cultured	NULL
in	NULL
RPMI	NULL
1640	NULL
,	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
FCS	NULL
(	NULL
Life	NULL
Technologies	NULL
)	NULL
,	NULL
2	NULL
mM	NULL
glutamine	NULL
,	NULL
100	NULL
U/ml	NULL
penicillin	NULL
,	NULL
100	NULL
pg/ml	NULL
streptomycin	NULL
at	NULL
37°C	NULL
in	NULL
5	NULL
%	NULL
CO	NULL
,	NULL
.	NULL

Generation	NULL
of	NULL
human	NULL
bone	NULL
marrow	NULL
CD3MADCs	NULL
The	NULL
generation	NULL
of	NULL
DCs	NULL
from	NULL
human	NULL
bone	NULL
marrow	NULL
CD34	NULL
*	NULL
stem	NULL
cell	NULL
was	NULL
as	NULL
described	NULL
previously	NULL
with	NULL
some	NULL
modification	NULL
(	NULL
39	NULL
)	NULL
.	NULL

Briefly	NULL
,	NULL
bone	NULL
marrow	NULL
suspensions	NULL
were	NULL
obtained	NULL
from	NULL
healthy	NULL
donors	NULL
for	NULL
allogeneic	NULL
transplan-	NULL
tation	NULL
under	NULL
the	NULL
permission	NULL
of	NULL
institutional	NULL
guidelines	NULL
.	NULL

CD34-positive	NULL
cells	NULL
(	NULL
purity	NULL
,	NULL
>	NULL
90	NULL
%	NULL
)	NULL
were	NULL
isolated	NULL
with	NULL
a	NULL
CD34	NULL
*	NULL
cell	NULL
immunomagnetic	NULL
bead	NULL
system	NULL
(	NULL
Miltenyi	NULL
Biotec	NULL
,	NULL
Bergische	NULL
Aladbach	NULL
,	NULL
Germany	NULL
)	NULL
.	NULL

CD34*	NULL
stem	NULL
cells	NULL
were	NULL
cultured	NULL
in	NULL
complete	NULL
medium	NULL
supplemented	NULL
with	NULL
GM-CSF	NULL
(	NULL
100	NULL
ng/ml	NULL
)	NULL
and	NULL
TNF-a	NULL
(	NULL
50	NULL
ng/m	NULL
!	NULL
)	NULL

.	NULL

Every	NULL
4	NULL
days	NULL
,	NULL
one-half	NULL
of	NULL
the	NULL
medium	NULL
was	NULL
refreshed	NULL
with	NULL
complete	NULL
medium	NULL
containing	NULL
a	NULL
double	NULL
concentration	NULL
of	NULL
GM-CSF	NULL
and	NULL
TNF-a	NULL
as	NULL
indicated	NULL
above	NULL
.	NULL

Cultured	NULL
cells	NULL
were	NULL
harvested	NULL
for	NULL
analysis	NULL
of	NULL
surface	NULL
phenotype	NULL
at	NULL
different	NULL
stages	NULL
of	NULL
development	NULL
.	NULL

Up	NULL
to	NULL
the	NULL
12th	NULL
day	NULL
of	NULL
culture	NULL
,	NULL
CD34DC	NULL
suspensions	NULL
(	NULL
>	NULL
95	NULL
%	NULL
pure	NULL
as	NULL
confirmed	NULL
by	NULL
analysis	NULL
of	NULL
relatively	NULL
DC-specific	NULL
phenotype	NULL
and	NULL
with	NULL
a	NULL
typical	NULL
DC	NULL
mor-phology	NULL
)	NULL
were	NULL
collected	NULL
for	NULL
experimental	NULL
purposes	NULL
.	NULL

Generation	NULL
of	NULL
human	NULL
peripheral	NULL
blood	NULL
MoDCs	NULL
DCs	NULL
were	NULL
generated	NULL
from	NULL
human	NULL
peripheral	NULL
blood	NULL
monocytes	NULL
as	NULL
described	NULL
previously	NULL
with	NULL
minor	NULL
modifications	NULL
(	NULL
40	NULL
)	NULL
.	NULL

Briefly	NULL
,	NULL
PBMC	NULL
were	NULL
obtained	NULL
from	NULL
buffy	NULL
coats	NULL
from	NULL
heparinized	NULL
whole	NULL
blood	NULL
of	NULL
healthy	NULL
donors	NULL
(	NULL
the	NULL
Blood	NULL
Bank	NULL
of	NULL
Shanghai	NULL
,	NULL
Shanghai	NULL
,	NULL
China	NULL
)	NULL
by	NULL
density	NULL
gradient	NULL
centrifugation	NULL
on	NULL
Histopaque	NULL
1077	NULL
(	NULL
Sigma	NULL
)	NULL
.	NULL

These	NULL
cells	NULL
were	NULL
resuspended	NULL
in	NULL
serum-free	NULL
RPMI	NULL
1640	NULL
and	NULL
allowed	NULL
to	NULL
adhere	NULL
to	NULL
six-well	NULL
plates	NULL
(	NULL
Costar	NULL
,	NULL
Cambridge	NULL
,	NULL
MA	NULL
)	NULL
at	NULL
a	NULL
final	NULL
concentration	NULL
of	NULL
1	NULL
X	NULL
10	NULL
``	NULL
cells/3	NULL
ml/well	NULL
.	NULL

After	NULL
2	NULL
h	NULL
at	NULL
37°C	NULL
,	NULL
nonadherent	NULL
cells	NULL
were	NULL
gently	NULL
removed	NULL
with	NULL
warm	NULL
medium	NULL
.	NULL

The	NULL
resulting	NULL
adherent	NULL
cells	NULL
were	NULL
cultured	NULL
in	NULL
medium	NULL
supplemented	NULL
with	NULL
GM-CSF	NULL
(	NULL
100	NULL
ng/m	NULL
!	NULL
)	NULL

and	NULL
IL-4	NULL
(	NULL
100	NULL
ng/m	NULL
!	NULL
)	NULL

in	NULL
5	NULL
%	NULL
CO	NULL
,	NULL
;	NULL
at	NULL
37°C	NULL
.	NULL

Every	NULL
2	NULL
days	NULL
,	NULL
one-half	NULL
of	NULL
the	NULL
medium	NULL
was	NULL
replaced	NULL
by	NULL
fresh	NULL
medium	NULL
containing	NULL
double	NULL
concentration	NULL
of	NULL
GM-CSF	NULL
and	NULL
IL-4	NULL
as	NULL
indicated	NULL
above	NULL
.	NULL

Cell	NULL
suspensions	NULL
were	NULL
collected	NULL
for	NULL
analysis	NULL
of	NULL
surface	NULL
phenotype	NULL
at	NULL
different	NULL
stages	NULL
of	NULL
development	NULL
.	NULL

After	NULL
5	NULL
days	NULL
of	NULL
culture	NULL
,	NULL
MoDCs	NULL
were	NULL
harvested	NULL
for	NULL
subsequent	NULL
experiments	NULL
(	NULL
>	NULL
90	NULL
%	NULL
pure	NULL
as	NULL
confirmed	NULL
by	NULL
analysis	NULL
of	NULL
relatively	NULL
DC	NULL
-specific	NULL
phenotype	NULL
and	NULL
with	NULL
a	NULL
typical	NULL
DC	NULL
morphology	NULL
)	NULL
.	NULL

Flow	NULL
cytometry	NULL
Phenotypic	NULL
analysis	NULL
was	NULL
performed	NULL
by	NULL
FACS	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
41	NULL
)	NULL
.	NULL

DCs	NULL
(	NULL
5	NULL
X	NULL
10°/ml	NULL
)	NULL
were	NULL
washed	NULL
,	NULL
resuspended	NULL
in	NULL
cold	NULL
PBS	NULL
containing	NULL
0.1	NULL
%	NULL
sodium	NULL
azide	NULL
(	NULL
Sigma	NULL
)	NULL
and	NULL
10	NULL
%	NULL
mouse	NULL
serum	NULL
,	NULL
and	NULL
then	NULL
incubated	NULL
for	NULL
10	NULL
min	NULL
at	NULL
4°C	NULL
.	NULL

Subsequently	NULL
,	NULL
they	NULL
were	NULL
incubated	NULL
with	NULL
FITC-	NULL
or	NULL
PE-labeled	NULL
mAbs	NULL
specific	NULL
for	NULL
human	NULL
CD14	NULL
,	NULL
CD86	NULL
,	NULL
CD40	NULL
,	NULL
CD§83	NULL
,	NULL
HLA-DR	NULL
,	NULL
or	NULL
iso-type-matched	NULL
controls	NULL
(	NULL
5	NULL
pg/ml	NULL
!	NULL
)	NULL

for	NULL
30	NULL
min	NULL
at	NULL
4°C	NULL
in	NULL
PBS	NULL
.	NULL

For	NULL
analysis	NULL
of	NULL
TRAIL	NULL
expression	NULL
,	NULL
DCs	NULL
were	NULL
labeled	NULL
with	NULL
antihuman	NULL
TRAIL	NULL
mAb	NULL
(	NULL
5	NULL
or	NULL
antihuman	NULL
IgG2b	NULL
(	NULL
5	NULL
pg/ml	NULL
)	NULL
for	NULL
30	NULL
min	NULL
at	NULL
4°C	NULL
.	NULL

After	NULL
2	NULL
washes	NULL
,	NULL
cells	NULL
were	NULL
incubated	NULL
with	NULL
FITC-labeled	NULL
secondary	NULL
Ab	NULL
(	NULL
5	NULL
pg/ml	NULL
)	NULL
for	NULL
another	NULL
30	NULL
min	NULL
at	NULL
4°C	NULL
.	NULL

Stained	NULL
cells	NULL
were	NULL
analyzed	NULL
by	NULL
FACSCaliber	NULL
flow	NULL
cytometry	NULL
(	NULL
Becton	NULL
Dickinson	NULL
,	NULL
Mountain	NULL
View	NULL
,	NULL
CA	NULL
)	NULL
and	NULL
CellQuest	NULL
software	NULL
(	NULL
Becton	NULL
Dickinson	NULL
)	NULL
.	NULL

Dead	NULL
cells	NULL
were	NULL
excluded	NULL
by	NULL
gating	NULL
out	NULL
propidium	NULL
iodide-positive	NULL
cells	NULL
.	NULL

MTT	NULL
reduction	NULL
assay	NULL
for	NULL
growth	NULL
inhibition	NULL
of	NULL
tumor	NULL
cells	NULL
by	NULL
TRAIL	NULL
Tumor	NULL
cells	NULL
were	NULL
plated	NULL
in	NULL
96-well	NULL
plates	NULL
at	NULL
5	NULL
X	NULL
10°	NULL
cells/well	NULL
.	NULL

TRAIL	NULL
(	NULL
100	NULL
ng/m	NULL
!	NULL
)	NULL

and	NULL
TRAIL	NULL
enhancer	NULL
(	NULL
500	NULL
ng/m	NULL
!	NULL
)	NULL

were	NULL
added	NULL
at	NULL
the	NULL
indicated	NULL
concentrations	NULL
.	NULL

Each	NULL
concentration	NULL
was	NULL
performed	NULL
in	NULL
triplicate	NULL
.	NULL

After	NULL
culture	NULL
at	NULL
37°C	NULL
for	NULL
24	NULL
h	NULL
,	NULL
20	NULL
ul	NULL
MTT	NULL
(	NULL
5	NULL
mg/m	NULL
!	NULL
)	NULL

were	NULL
added	NULL
to	NULL
each	NULL
well	NULL
for	NULL
another	NULL
4	NULL
h.	NULL
Plates	NULL
were	NULL
centrifuged	NULL
at	NULL
1000	NULL
rpm	NULL
for	NULL
5	NULL
min	NULL
,	NULL
and	NULL
then	NULL
supernatants	NULL
were	NULL
gently	NULL
removed	NULL
.	NULL

DMSO	NULL
(	NULL
100	NULL
Ll	NULL
;	NULL
Sigma	NULL
)	NULL
was	NULL
added	NULL
to	NULL
each	NULL
well	NULL
to	NULL
dissolve	NULL
formazan	NULL
.	NULL

The	NULL
OD	NULL
of	NULL
each	NULL
well	NULL
was	NULL
read	NULL
using	NULL
a	NULL
microplate	NULL
reader	NULL
(	NULL
model	NULL
550	NULL
;	NULL
Bio-Rad	NULL
,	NULL
Hercules	NULL
,	NULL
CA	NULL
)	NULL
at	NULL
570	NULL
nm	NULL
.	NULL

The	NULL
percent	NULL
of	NULL
growth	NULL
inhibition	NULL
was	NULL
calculated	NULL
as	NULL
:	NULL
growth	NULL
inhibition	NULL
(	NULL
%	NULL
)	NULL
=	NULL
[	NULL
1	NULL
-	NULL
(	NULL
experimental	NULL
group	NULL
(	NULL
OD	NULL
)	NULL
/control	NULL
group	NULL
(	NULL
OD	NULL
)	NULL
)	NULL
]	NULL
X	NULL
100	NULL
.	NULL

Data	NULL
were	NULL
expressed	NULL
as	NULL
the	NULL
mean	NULL
+	NULL
SD	NULL
of	NULL
triplicate	NULL
wells	NULL
.	NULL

Assay	NULL
for	NULL
DC-mediated	NULL
cytotoxicity	NULL
DC-mediated	NULL
cytotoxicity	NULL
to	NULL
tumor	NULL
cells	NULL
was	NULL
measured	NULL
by	NULL
an	NULL
18-h	NULL
``	NULL
'Cr	NULL
release	NULL
assay	NULL
.	NULL

This	NULL
method	NULL
was	NULL
as	NULL
previously	NULL
described	NULL
with	NULL
some	NULL
modification	NULL
(	NULL
42	NULL
)	NULL
.	NULL

Human	NULL
MoDCs	NULL
(	NULL
cultured	NULL
for	NULL
5	NULL
days	NULL
from	NULL
CD14	NULL
*	NULL
monocytes	NULL
)	NULL
and	NULL
CD34DCs	NULL
(	NULL
cultured	NULL
for	NULL
12	NULL
days	NULL
from	NULL
CD34*	NULL
stem	NULL
cells	NULL
)	NULL
were	NULL
incubated	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
LPS	NULL
(	NULL
100	NULL
ng/m	NULL
!	NULL
)	NULL

or	NULL
(	NULL
100	NULL
ng/ml	NULL
!	NULL
)	NULL

or	NULL
in	NULL
medium	NULL
alone	NULL
for	NULL
12	NULL
h	NULL
and	NULL
then	NULL
washed	NULL
.	NULL

Tumor	NULL
cells	NULL
(	NULL
1	NULL
X	NULL
10	NULL
``	NULL
cells/ml	NULL
!	NULL
)	NULL

were	NULL
labeled	NULL
with	NULL
100	NULL
pCi	NULL
Na	NULL
,	NULL
``	NULL
``	NULL
CrO	NULL
,	NULL
(	NULL
Amersham	NULL
,	NULL
Arlington	NULL
Heights	NULL
,	NULL
IL	NULL
)	NULL
for	NULL
1	NULL
h	NULL
at	NULL
37°C	NULL
.	NULL

5	NULL
``	NULL
Cr-labeled	NULL
tumor	NULL
cells	NULL
were	NULL
cocultured	NULL
with	NULL
CD34	NULL
*DCs	NULL
or	NULL
MoDCs	NULL
as	NULL
described	NULL
at	NULL
the	NULL
indicated	NULL
E	NULL
:	NULL
T	NULL
ratios	NULL
for	NULL
18	NULL
h.	NULL
In	NULL
some	NULL
experiments	NULL
,	NULL
stimulated	NULL
and	NULL
unstimulated	NULL
CD34DCs	NULL
or	NULL
MoDCs	NULL
were	NULL
pretreated	NULL
with	NULL
TRAILR3-Fc	NULL
(	NULL
1	NULL
pg/ml	NULL
!	NULL
)	NULL

or	NULL
isotype	NULL
control	NULL
human	NULL
IgG1	NULL
(	NULL
1	NULL
ug/tol	NULL
)	NULL
30	NULL
min	NULL
before	NULL
coincubation	NULL
with	NULL
labeled	NULL
tumor	NULL
cells	NULL
.	NULL

In	NULL
other	NULL
experiments	NULL
,	NULL
*'Cr-labeled	NULL
tumor	NULL
cells	NULL
were	NULL
pretreated	NULL
with	NULL
caspase-3	NULL
inhibitor	NULL
(	NULL
50	NULL
M	NULL
)	NULL
or	NULL
NF-KB	NULL
inhibitor	NULL
(	NULL
15	NULL
M	NULL
)	NULL
for	NULL
30	NULL
min	NULL
before	NULL
coculture	NULL
with	NULL
stimulated	NULL
or	NULL
unstimulated	NULL
DCs	NULL
.	NULL

Each	NULL
well	NULL
contained	NULL
a	NULL
total	NULL
volume	NULL
of	NULL
200	NULL
ul	NULL
medium	NULL
in	NULL
96-well	NULL
round-bottom	NULL
plates	NULL
(	NULL
Costar	NULL
)	NULL
.	NULL

After	NULL
coculture	NULL
,	NULL
100	NULL
6107	NULL
'0t	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
[	NULL
810	NULL
fountwrut	NULL
[	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
The	NULL
Journal	NULL
of	NULL
Immunology	NULL
5409	NULL
Table	NULL
I	NULL
.	NULL

-	NULL
Relative	NULL
DC-specific	NULL
phenotypes	NULL
and	NULL
TRAIL	NULL
expression	NULL
on	NULL
the	NULL
CD34DCs	NULL
during	NULL
differentiation	NULL
and	NULL
development	NULL
``	NULL
Time	NULL
of	NULL
%	NULL
of	NULL
Cultured	NULL
Cells	NULL
Expressing	NULL
Specific	NULL
Molecules	NULL
``	NULL
Culture	NULL
(	NULL
days	NULL
)	NULL
CD34	NULL
CD14	NULL
HLA-DR	NULL
CD40	NULL
CD86	NULL
CD83	NULL
TRALL	NULL
0	NULL
94.30	NULL
ND®	NULL
ND	NULL
ND	NULL
ND	NULL
ND	NULL
4.96	NULL
4	NULL
ND	NULL
20.02	NULL
46.33	NULL
11.00	NULL
9.67	NULL
13.84	NULL
6.62	NULL
8	NULL
ND	NULL
63.56	NULL
79.89	NULL
18.85	NULL
12.83	NULL
10.59	NULL
41.11	NULL
10	NULL
ND	NULL
27.63	NULL
85.06	NULL
21.34	NULL
41.46	NULL
9.43	NULL
40.27	NULL
14	NULL
ND	NULL
4.11	NULL
98.60	NULL
57.87	NULL
61.51	NULL
28.94	NULL
43.67	NULL
``	NULL
Data	NULL
are	NULL
representative	NULL
of	NULL
three	NULL
independent	NULL
experiments	NULL
.	NULL

*	NULL
Percents	NULL
of	NULL
cultured	NULL
cells	NULL
staining	NULL
by	NULL
isotype	NULL
control	NULL
mAbs	NULL
were	NULL
all	NULL
<	NULL
5	NULL
%	NULL
.	NULL

©	NULL
ND	NULL
,	NULL
Not	NULL
detected	NULL
.	NULL

ul	NULL
of	NULL
supernatants	NULL
were	NULL
collected	NULL
,	NULL
and	NULL
their	NULL
radioactivity	NULL
was	NULL
measured	NULL
in	NULL
a	NULL
gamma	NULL
counter	NULL
(	NULL
1275	NULL
;	NULL
Wallac	NULL
,	NULL
Turku	NULL
,	NULL
Finland	NULL
)	NULL
.	NULL

Total	NULL
and	NULL
spontaneous	NULL
Cr	NULL
release	NULL
values	NULL
were	NULL
obtained	NULL
as	NULL
cpm	NULL
from	NULL
supernatants	NULL
of	NULL
target	NULL
cells	NULL
in	NULL
1	NULL
%	NULL
Nonidet	NULL
P-40	NULL
or	NULL
in	NULL
medium	NULL
alone	NULL
,	NULL
respectively	NULL
.	NULL

Spontaneous	NULL
release	NULL
was	NULL
<	NULL
15	NULL
%	NULL
of	NULL
maximum	NULL
.	NULL

TRAIL-R3-Fc	NULL
and	NULL
IgG1	NULL
were	NULL
not	NULL
toxic	NULL
to	NULL
target	NULL
cells	NULL
.	NULL

NF-KB	NULL
inhibitor	NULL
(	NULL
15	NULL
M	NULL
)	NULL
and	NULL
caspase-3	NULL
inhibitor	NULL
(	NULL
50	NULL
M	NULL
)	NULL
also	NULL
had	NULL
mo	NULL
effect	NULL
on	NULL
the	NULL
spontaneous	NULL
release	NULL
of	NULL
radioisotope	NULL
from	NULL
target	NULL
cells	NULL
.	NULL

Caspase-3	NULL
inhibitor	NULL
did	NULL
not	NULL
decrease	NULL
the	NULL
viability	NULL
of	NULL
DCs	NULL
.	NULL

NF-KB	NULL
inhibitor	NULL
slightly	NULL
decreased	NULL
the	NULL
viability	NULL
of	NULL
DCs	NULL
but	NULL
had	NULL
no	NULL
effect	NULL
on	NULL
the	NULL
cytotoxicity	NULL
of	NULL
DCs	NULL
.	NULL

All	NULL
experiments	NULL
were	NULL
performed	NULL
in	NULL
triplicate	NULL
or	NULL
sextuplicate	NULL
wells	NULL
.	NULL

The	NULL
percentage	NULL
of	NULL
cytotoxicity	NULL
was	NULL
calculated	NULL
as	NULL
:	NULL
cytotoxicity	NULL
(	NULL
%	NULL
)	NULL
=	NULL
[	NULL
(	NULL
ex-perimental	NULL
group	NULL
cpm	NULL
-	NULL
spontaneous	NULL
cpm	NULL
)	NULL
/	NULL
(	NULL
total	NULL
cpm	NULL
-	NULL
spontaneous	NULL
cpm	NULL
)	NULL
]	NULL
X	NULL
100	NULL
.	NULL

Analysis	NULL
of	NULL
caspase	NULL
activation	NULL
by	NULL
Western	NULL
blotting	NULL
HL6O	NULL
cells	NULL
or	NULL
Reh	NULL
cells	NULL
(	NULL
1	NULL
X	NULL
10	NULL
``	NULL
cells/3	NULL
ml/group	NULL
)	NULL
were	NULL
cultured	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
TRAIL	NULL
(	NULL
100	NULL
ng/m	NULL
!	NULL
)	NULL

plus	NULL
TRAIL	NULL
enhancer	NULL
(	NULL
500	NULL
ng/ml	NULL
)	NULL
for	NULL
the	NULL
indicated	NULL
time	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
then	NULL
harvested	NULL
,	NULL
and	NULL
media	NULL
were	NULL
removed	NULL
by	NULL
two	NULL
rinsings	NULL
with	NULL
ice-cold	NULL
PBS	NULL
.	NULL

Cells	NULL
were	NULL
lysed	NULL
in	NULL
0.5	NULL
ml	NULL
ice-cold	NULL
lysis	NULL
buffer	NULL
(	NULL
1	NULL
%	NULL
Nonidet	NULL
P-40	NULL
,	NULL
20	NULL
mMTris-HCI	NULL
(	NULL
pH	NULL
8.0	NULL
)	NULL
,	NULL
10	NULL
%	NULL
glycerol	NULL
,	NULL
137	NULL
mM	NULL
NaCl	NULL
,	NULL
2	NULL
mM	NULL
EDTA	NULL
,	NULL
10	NULL
pg/ml	NULL
aprotinin	NULL
,	NULL
10	NULL
ug/ml	NULL
leupeptin	NULL
,	NULL
1	NULL
mM	NULL
PMSF	NULL
,	NULL
and	NULL
1	NULL
mM	NULL
sodium	NULL
o-vanadate	NULL
)	NULL
for	NULL
5	NULL
min	NULL
on	NULL
ice	NULL
.	NULL

Cell	NULL
lysates	NULL
were	NULL
transferred	NULL
to	NULL
a	NULL
new	NULL
tube	NULL
after	NULL
centrifugation	NULL
at	NULL
10,000	NULL
X	NULL
g	NULL
for	NULL
10	NULL
min	NULL
at	NULL
4°C	NULL
and	NULL
if	NULL
necessary	NULL
stored	NULL
at	NULL
-80°C	NULL
.	NULL

Equal	NULL
volumes	NULL
of	NULL
cell	NULL
lysates	NULL
in	NULL
elec-trophoresis	NULL
sample	NULL
buffer	NULL
were	NULL
boiled	NULL
for	NULL
3	NULL
min	NULL
and	NULL
then	NULL
resolved	NULL
on	NULL
a	NULL
12	NULL
%	NULL
separating	NULL
polyacrylamide	NULL
slab	NULL
gel	NULL
.	NULL

After	NULL
electrophoresis	NULL
,	NULL
the	NULL
proteins	NULL
were	NULL
electrotransferred	NULL
to	NULL
nitrocellulose	NULL
membranes	NULL
.	NULL

After	NULL
blocking	NULL
with	NULL
5	NULL
%	NULL
nonfat	NULL
dried	NULL
milk	NULL
in	NULL
0.1	NULL
%	NULL
Tween	NULL
20	NULL
+	NULL
PBS	NULL
for	NULL
1	NULL
h	NULL
at	NULL
room	NULL
temperature	NULL
,	NULL
the	NULL
membrane	NULL
was	NULL
incubated	NULL
with	NULL
primary	NULL
Ab	NULL
(	NULL
specific	NULL
for	NULL
caspase-3	NULL
p20	NULL
or	NULL
caspase-8	NULL
p20	NULL
)	NULL
at	NULL
a	NULL
1/500	NULL
dilution	NULL
overnight	NULL
at	NULL
4°C	NULL
.	NULL

Then	NULL
the	NULL
membrane	NULL
was	NULL
incubated	NULL
with	NULL
HRP-conjugated	NULL
secondary	NULL
Ab	NULL
and	NULL
detected	NULL
by	NULL
chemi-luminescence	NULL
(	NULL
Santa	NULL
Cruz	NULL
Biotechnology	NULL
)	NULL
.	NULL

Statistics	NULL
The	NULL
Student	NULL
1	NULL
test	NULL
was	NULL
used	NULL
for	NULL
analyzing	NULL
whether	NULL
the	NULL
differences	NULL
between	NULL
the	NULL
values	NULL
of	NULL
the	NULL
test	NULL
groups	NULL
and	NULL
those	NULL
of	NULL
the	NULL
relevant	NULL
controls	NULL
were	NULL
sig-nificant	NULL
.	NULL

p	NULL
<	NULL
0.05	NULL
was	NULL
regarded	NULL
as	NULL
statistically	NULL
significance	NULL
.	NULL

Data	NULL
are	NULL
shown	NULL
as	NULL
the	NULL
mean	NULL
+	NULL
SD	NULL
of	NULL
triplicate	NULL
wells	NULL
.	NULL

Results	NULL
TRAIL	NULL
expression	NULL
on	NULL
human	NULL
DCs	NULL
derived	NULL
from	NULL
CD34	NULL
``	NULL
stem	NULL
cells	NULL
or	NULL
peripheral	NULL
blood	NULL
monocytes	NULL
We	NULL
detected	NULL
the	NULL
kinetic	NULL
expression	NULL
of	NULL
TRAIL	NULL
on	NULL
two	NULL
kinds	NULL
of	NULL
distinct	NULL
precursor-derived	NULL
DCs	NULL
,	NULL
CD34DCs	NULL
and	NULL
MoDCs	NULL
,	NULL
during	NULL
their	NULL
differentiation	NULL
and	NULL
development	NULL
in	NULL
vitro	NULL
.	NULL

CD34DC	NULL
's	NULL
were	NULL
generated	NULL
from	NULL
CD34	NULL
*	NULL
hemopoietic	NULL
progenitors	NULL
in	NULL
bone	NULL
marrow	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
GM-CSF	NULL
plus	NULL
TNF-	NULL
«	NULL
for	NULL
14	NULL
days	NULL
.	NULL

During	NULL
this	NULL
period	NULL
,	NULL
we	NULL
examined	NULL
TRAIL	NULL
expression	NULL
and	NULL
DC-specific	NULL
phenotype	NULL
on	NULL
the	NULL
cultured	NULL
cells	NULL
at	NULL
different	NULL
stages	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Table	NULL
I	NULL
,	NULL
CD34	NULL
*	NULL
stem	NULL
cells	NULL
(	NULL
purity	NULL
up	NULL
to	NULL
94	NULL
%	NULL
)	NULL
did	NULL
not	NULL
express	NULL
TRAIL	NULL
.	NULL

After	NULL
4	NULL
days	NULL
of	NULL
culture	NULL
,	NULL
these	NULL
cells	NULL
still	NULL
did	NULL
not	NULL
express	NULL
TRAIL	NULL
,	NULL
the	NULL
costimulatory	NULL
molecules	NULL
CD86	NULL
and	NULL
CD40	NULL
,	NULL
the	NULL
monocyte	NULL
marker	NULL
CD14	NULL
,	NULL
or	NULL
the	NULL
DC	NULL
maturity	NULL
marker	NULL
CD83	NULL
;	NULL
but	NULL
did	NULL
express	NULL
moderate	NULL
levels	NULL
of	NULL
HLA-DR	NULL
.	NULL

Expression	NULL
of	NULL
TRAIL	NULL
was	NULL
evident	NULL
on	NULL
the	NULL
8th	NULL
day	NULL
of	NULL
culture	NULL
,	NULL
along	NULL
with	NULL
CD14	NULL
and	NULL
CD40	NULL
.	NULL

HLA-DR	NULL
expression	NULL
was	NULL
also	NULL
up-regulated	NULL
at	NULL
this	NULL
time	NULL
,	NULL
but	NULL
CD86	NULL
and	NULL
CD83	NULL
molecules	NULL
were	NULL
not	NULL
yet	NULL
expressed	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
adherent	NULL
DC-like	NULL
clusters	NULL
could	NULL
be	NULL
seen	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

By	NULL
the	NULL
10th	NULL
day	NULL
of	NULL
culture	NULL
,	NULL
levels	NULL
of	NULL
TRAIL	NULL
remained	NULL
constant	NULL
,	NULL
and	NULL
the	NULL
phenotype	NULL
revealed	NULL
that	NULL
the	NULL
DCs	NULL
were	NULL
still	NULL
immature	NULL
,	NULL
although	NULL
they	NULL
showed	NULL
the	NULL
appearance	NULL
of	NULL
typical	NULL
veils	NULL
or	NULL
dendritic	NULL
processes	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

On	NULL
the	NULL
14th	NULL
day	NULL
of	NULL
culture	NULL
,	NULL
TRAIL	NULL
expression	NULL
was	NULL
still	NULL
stable	NULL
.	NULL

HLA-DR	NULL
was	NULL
expressed	NULL
on	NULL
up	NULL
to	NULL
98	NULL
%	NULL
of	NULL
cells	NULL
,	NULL
the	NULL
costimulatory	NULL
molecules	NULL
CD86	NULL
and	NULL
CD40	NULL
were	NULL
expressed	NULL
on	NULL
more	NULL
than	NULL
one-half	NULL
of	NULL
cells	NULL
,	NULL
CD14	NULL
was	NULL
down-regulated	NULL
to	NULL
control	NULL
level	NULL
,	NULL
and	NULL
the	NULL
CD83	NULL
maturation	NULL
marker	NULL
was	NULL
expressed	NULL
,	NULL
which	NULL
suggested	NULL
that	NULL
at	NULL
this	NULL
stage	NULL
mature	NULL
DCs	NULL
were	NULL
present	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
<	NULL
5	NULL
%	NULL
of	NULL
cultured	NULL
cells	NULL
expressed	NULL
CD3	NULL
,	NULL
CD16	NULL
,	NULL
or	NULL
CD19	NULL
after	NULL
8	NULL
days	NULL
of	NULL
culture	NULL
,	NULL
showing	NULL
that	NULL
there	NULL
was	NULL
very	NULL
little	NULL
contamination	NULL
with	NULL
T	NULL
cells	NULL
,	NULL
NK	NULL
cells	NULL
,	NULL
or	NULL
B	NULL
cells	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

In	NULL
summary	NULL
,	NULL
TRAIL	NULL
expression	NULL
appeared	NULL
in	NULL
the	NULL
middle	NULL
of	NULL
CD34DC	NULL
differentiation	NULL
and	NULL
the	NULL
level	NULL
was	NULL
maintained	NULL
until	NULL
the	NULL
mature	NULL
stage	NULL
.	NULL

MoDC	NULL
's	NULL
were	NULL
induced	NULL
from	NULL
peripheral	NULL
blood	NULL
CD14	NULL
*	NULL
monocytes	NULL
cultured	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
GM-CSF	NULL
plus	NULL
IL-4	NULL
for	NULL
7	NULL
days	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Table	NULL
II	NULL
,	NULL
TRAIL	NULL
expression	NULL
was	NULL
detected	NULL
on	NULL
freshly	NULL
isolated	NULL
monocytes	NULL
(	NULL
purity	NULL
up	NULL
to	NULL
99	NULL
%	NULL
)	NULL
,	NULL
and	NULL
the	NULL
level	NULL
of	NULL
TRAIL	NULL
expression	NULL
was	NULL
moderate	NULL
.	NULL

After	NULL
7	NULL
days	NULL
of	NULL
culture	NULL
,	NULL
the	NULL
cells	NULL
expressed	NULL
high	NULL
levels	NULL
of	NULL
HLA-DR	NULL
,	NULL
moderate	NULL
levels	NULL
of	NULL
the	NULL
costimulatory	NULL
molecules	NULL
CD86	NULL
and	NULL
CD40	NULL
and	NULL
the	NULL
maturation	NULL
marker	NULL
CD83	NULL
,	NULL
but	NULL
no	NULL
CD14	NULL
.	NULL

Moreover	NULL
,	NULL
they	NULL
showed	NULL
veiled	NULL
or	NULL
dendritic	NULL
morphology	NULL
,	NULL
indicating	NULL
that	NULL
they	NULL
were	NULL
mature	NULL
MoDCs	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
contamination	NULL
with	NULL
cells	NULL
of	NULL
other	NULL
lineages	NULL
(	NULL
CD3	NULL
T	NULL
cells	NULL
,	NULL
CD16	NULL
NK	NULL
cells	NULL
,	NULL
and	NULL
Table	NULL
II	NULL
.	NULL

Relative	NULL
DC-specific	NULL
phenotypes	NULL
and	NULL
TRAIL	NULL
expression	NULL
on	NULL
the	NULL
MoDCs	NULL
at	NULL
different	NULL
developmental	NULL
stages	NULL
``	NULL
Time	NULL
of	NULL
%	NULL
of	NULL
Cultured	NULL
Cells	NULL
Expressing	NULL
Specific	NULL
Molecules	NULL
``	NULL
Culture	NULL
(	NULL
days	NULL
)	NULL
CD14	NULL
HLA-DR	NULL
CD86	NULL
CD40	NULL
CD83	NULL
TRAIL	NULL
0	NULL
99.43	NULL
ND®	NULL
ND	NULL
ND	NULL
ND	NULL
36.75	NULL
3	NULL
59.58	NULL
79.08	NULL
9.99	NULL
11.30	NULL
3.20	NULL
39.41	NULL
7	NULL
9.28	NULL
95.11	NULL
52.50	NULL
68.01	NULL
52.00	NULL
28.86	NULL
``	NULL
Data	NULL
are	NULL
representative	NULL
of	NULL
three	NULL
independent	NULL
experiments	NULL
.	NULL

*	NULL
Percents	NULL
of	NULL
cultured	NULL
cells	NULL
staining	NULL
by	NULL
isotype	NULL
control	NULL
mAbs	NULL
were	NULL
all	NULL
<	NULL
5	NULL
%	NULL
.	NULL

©	NULL
ND	NULL
,	NULL
Not	NULL
detected	NULL
.	NULL

6107	NULL
'0t	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
[	NULL
810	NULL
fountwrut	NULL
[	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
5410	NULL
isotype	NULL
control	NULL
unstimulated	NULL
CYTOTOXICITY	NULL
OF	NULL
IFN-B-STIMULATED	NULL
HUMAN	NULL
DC	NULL
TO	NULL
TUMOR	NULL
CELLS	NULL
LPS-stimulated	NULL
IFN-beta-stimulated	NULL
3	NULL
8	NULL
8	NULL
€	NULL
~4	NULL
4.86	NULL
%	NULL
~4	NULL
34.44	NULL
%	NULL
~4	NULL
32.10	NULL
%	NULL
~4	NULL
59.59	NULL
%	NULL
n	NULL
woo	NULL
4	NULL
w	NULL
-	NULL
4	NULL
2	NULL
4	NULL
CD34DC	NULL
€	NULL
€	NULL
5	NULL
3	NULL
CI	NULL
o	NULL
-	NULL
9	NULL
-	NULL
9	NULL
e	NULL
5	NULL
©	NULL
o	NULL
9	NULL
1	NULL
o	NULL
;	NULL
»	NULL
i1f	NULL
_	NULL
MM	NULL
o	NULL
i1uZ	NULL
'	NULL
,	NULL
T	NULL
T	NULL
I	NULL
T	NULL
U	NULL
T	NULL
T	NULL
U	NULL
I	NULL
10	NULL
``	NULL
ao	NULL
!	NULL

iof	NULL
40	NULL
%	NULL
40	NULL
``	NULL
10	NULL
%	NULL
ae	NULL
!	NULL

aot	NULL
aot	NULL
ao	NULL
``	NULL
10°	NULL
ao	NULL
!	NULL

aof	NULL
aot	NULL
ant	NULL
FL14	NULL
]	NULL
Lik	NULL
FL14	NULL
t	NULL
4.83	NULL
%	NULL
34.75	NULL
%	NULL
Ne	NULL
a	NULL
30.10	NULL
%	NULL
97.28	NULL
%	NULL
MoDC	NULL
a	NULL
#	NULL
o	NULL
4	NULL
}	NULL
#	NULL
04	NULL
j	NULL
x	NULL
o	NULL
¥	NULL
.	NULL

I.	NULL
y	NULL
M1I	NULL
l	NULL
o	NULL
iZ	NULL
``	NULL
M1	NULL
o	NULL
¥	NULL
,	NULL
108	NULL
ao	NULL
!	NULL

ao	NULL
``	NULL
10°	NULL
10	NULL
``	NULL
10	NULL
%	NULL
ao	NULL
!	NULL

40°	NULL
(	NULL
0	NULL
%	NULL
ao	NULL
``	NULL
10	NULL
%	NULL
ao	NULL
ao	NULL
``	NULL
40°	NULL
408	NULL
10	NULL
%	NULL
ao	NULL
!	NULL

aot	NULL
40°	NULL
ao	NULL
``	NULL
FL	NULL
1-Height	NULL
FL1-Height	NULL
FL1-Height	NULL
FLt-Height	NULL
FIGURE	NULL
1	NULL
.	NULL

TRAIL	NULL
expression	NULL
was	NULL
up-regulated	NULL
on	NULL
the	NULL
human	NULL
MoDCs	NULL
and	NULL
CD34DCs	NULL
stimulated	NULL
with	NULL
IFN-B	NULL
but	NULL
not	NULL
with	NULL
LPS	NULL
.	NULL

Human	NULL
MoDCs	NULL
(	NULL
cultured	NULL
for	NULL
5	NULL
days	NULL
)	NULL
or	NULL
CD34DCs	NULL
(	NULL
cultured	NULL
for	NULL
12	NULL
days	NULL
)	NULL
were	NULL
incubated	NULL
in	NULL
the	NULL
absence	NULL
or	NULL
presence	NULL
of	NULL
IFN-B	NULL
(	NULL
100	NULL
ng/m	NULL
!	NULL
)	NULL

or	NULL
LPS	NULL
(	NULL
100	NULL
ng/m	NULL
!	NULL
)	NULL

for	NULL
12	NULL
h	NULL
and	NULL
then	NULL
analyzed	NULL
for	NULL
TRAIL	NULL
expression	NULL
.	NULL

Dotted	NULL
line	NULL
,	NULL
Staining	NULL
by	NULL
isotype	NULL
control	NULL
mAb	NULL
;	NULL
solid	NULL
line	NULL
,	NULL
TRAIL	NULL
staining	NULL
on	NULL
unstimulated	NULL
DCs	NULL
,	NULL
LPS-stimulated	NULL
DCs	NULL
,	NULL
or	NULL
IFN-B-stimulated	NULL
DCs	NULL
.	NULL

The	NULL
percentage	NULL
of	NULL
gated	NULL
cells	NULL
expressing	NULL
TRAIL	NULL
is	NULL
shown	NULL
in	NULL
each	NULL
panel	NULL
.	NULL

Results	NULL
represent	NULL
one	NULL
consistent	NULL
result	NULL
from	NULL
at	NULL
least	NULL
three	NULL
independent	NULL
experiments	NULL
.	NULL

FL	NULL
,	NULL
fluorescence	NULL
;	NULL
H	NULL
,	NULL
height	NULL
.	NULL

CD19	NULL
B	NULL
cells	NULL
)	NULL
was	NULL
<	NULL
5	NULL
%	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

During	NULL
the	NULL
time	NULL
spanning	NULL
maturation	NULL
from	NULL
CD14*	NULL
monocytes	NULL
to	NULL
mature	NULL
MoDC	NULL
's	NULL
,	NULL
the	NULL
level	NULL
of	NULL
TRAIL	NULL
expression	NULL
was	NULL
slightly	NULL
down-regulated	NULL
.	NULL

Up-regulation	NULL
of	NULL
TRAIL	NULL
expression	NULL
on	NULL
the	NULL
surface	NULL
of	NULL
MoDCs	NULL
and	NULL
CD34DC	NULL
's	NULL
by	NULL
IFN-B	NULL
stimulation	NULL
Many	NULL
studies	NULL
have	NULL
shown	NULL
that	NULL
different	NULL
subpopulations	NULL
of	NULL
PBMC	NULL
can	NULL
express	NULL
TRAIL	NULL
under	NULL
certain	NULL
conditions	NULL
.	NULL

TRAIL	NULL
expression	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
be	NULL
up-regulated	NULL
on	NULL
CD3	NULL
-	NULL
NK1.1*~	NULL
NK	NULL
cells	NULL
after	NULL
IL-2	NULL
or	NULL
IL-15	NULL
stimulation	NULL
;	NULL
on	NULL
activated	NULL
T	NULL
cells	NULL
after	NULL
PHA	NULL
or	NULL
anti-CD3	NULL
mAb	NULL
stimulation	NULL
;	NULL
and	NULL
on	NULL
macrophages	NULL
or	NULL
CD11c*	NULL
DCs	NULL
after	NULL
IFN-y	NULL
or	NULL
IFN-a	NULL
«	NULL
stimulation	NULL
(	NULL
19	NULL
,	NULL
26	NULL
,	NULL
27	NULL
,	NULL
37	NULL
,	NULL
38	NULL
)	NULL
.	NULL

To	NULL
date	NULL
there	NULL
have	NULL
been	NULL
no	NULL
data	NULL
concerning	NULL
the	NULL
change	NULL
of	NULL
TRAIL	NULL
expression	NULL
on	NULL
CD34DCs	NULL
or	NULL
MoDCs	NULL
.	NULL

Considering	NULL
that	NULL
IFN-y	NULL
or	NULL
IFN-a	NULL
«	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
stimulate	NULL
TRAIL	NULL
expression	NULL
on	NULL
CD11¢c	NULL
'	NULL
DCs	NULL
,	NULL
we	NULL
evaluated	NULL
whether	NULL
IFN-B	NULL
could	NULL
also	NULL
produce	NULL
the	NULL
same	NULL
effect	NULL
on	NULL
CD34DCs	NULL
or	NULL
MoDCs	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
we	NULL
examined	NULL
the	NULL
effect	NULL
of	NULL
LPS	NULL
(	NULL
which	NULL
can	NULL
induce	NULL
DC	NULL
into	NULL
maturation	NULL
)	NULL
on	NULL
the	NULL
regulation	NULL
of	NULL
TRAIL	NULL
expression	NULL
of	NULL
DCs	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

1	NULL
,	NULL
the	NULL
level	NULL
of	NULL
TRAIL	NULL
on	NULL
the	NULL
12th	NULL
day	NULL
of	NULL
culture	NULL
of	NULL
CD34DCs	NULL
was	NULL
increased	NULL
by	NULL
IFN-B	NULL
stimulation	NULL
,	NULL
compared	NULL
with	NULL
levels	NULL
seen	NULL
in	NULL
unstimulated	NULL
CD34DCs	NULL
.	NULL

However	NULL
,	NULL
TRAIL	NULL
expression	NULL
was	NULL
downregulated	NULL
after	NULL
LPS	NULL
stimulation	NULL
.	NULL

When	NULL
MoDCs	NULL
cultured	NULL
for	NULL
5	NULL
days	NULL
were	NULL
examined	NULL
,	NULL
IFN-B	NULL
was	NULL
seen	NULL
to	NULL
significantly	NULL
up-regulate	NULL
TRAIL	NULL
expression	NULL
,	NULL
whereas	NULL
LPS	NULL
had	NULL
no	NULL
effect	NULL
.	NULL

Growth	NULL
inhibition	NULL
of	NULL
hemopoietic	NULL
origin	NULL
tumor	NULL
cells	NULL
by	NULL
TRAIL	NULL
Many	NULL
tumor	NULL
cells	NULL
of	NULL
hemopoietic-origin	NULL
are	NULL
sensitive	NULL
to	NULL
TRAIL-mediated	NULL
apoptosis	NULL
.	NULL

To	NULL
ascertain	NULL
whether	NULL
DCs	NULL
can	NULL
kill	NULL
tumor	NULL
cells	NULL
via	NULL
TRAIL	NULL
,	NULL
we	NULL
first	NULL
screened	NULL
for	NULL
TRAIL-sensitive	NULL
tumor	NULL
cell	NULL
lines	NULL
in	NULL
a	NULL
variety	NULL
of	NULL
tumor	NULL
cells	NULL
of	NULL
hemopoietic	NULL
origin	NULL
as	NULL
measured	NULL
by	NULL
the	NULL
MTT	NULL
reduction	NULL
assay	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

2	NULL
,	NULL
HL60	NULL
cells	NULL
and	NULL
Reh	NULL
cells	NULL
were	NULL
highly	NULL
sensitive	NULL
to	NULL
TRAIL-mediated	NULL
growth	NULL
inhibition	NULL
.	NULL

Obvious	NULL
cellular	NULL
debris	NULL
of	NULL
HL6O0	NULL
cells	NULL
or	NULL
Reh	NULL
cells	NULL
was	NULL
observed	NULL
under	NULL
the	NULL
microscope	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

However	NULL
,	NULL
no	NULL
obvious	NULL
growth	NULL
inhibition	NULL
of	NULL
other	NULL
tumor	NULL
cells	NULL
,	NULL
including	NULL
Jurkat	NULL
cells	NULL
,	NULL
Daudi	NULL
cells	NULL
,	NULL
and	NULL
U937	NULL
cells	NULL
,	NULL
was	NULL
observed	NULL
under	NULL
the	NULL
indicated	NULL
range	NULL
of	NULL
TRAIL	NULL
concentrations	NULL
,	NULL
which	NULL
was	NULL
inconsistent	NULL
with	NULL
previous	NULL
reports	NULL
(	NULL
33	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
in	NULL
our	NULL
system	NULL
,	NULL
HL6O0	NULL
cells	NULL
and	NULL
Reh	NULL
cells	NULL
were	NULL
determined	NULL
as	NULL
the	NULL
TRAIL-sensitive	NULL
tumor	NULL
cells	NULL
for	NULL
the	NULL
following	NULL
experiments	NULL
.	NULL

Involvement	NULL
of	NULL
TRAIL	NULL
in	NULL
the	NULL
cytotoxicity	NULL
of	NULL
IFN-B-stimulated	NULL
DCs	NULL
against	NULL
HL6O	NULL
cells	NULL
and	NULL
Reh	NULL
cells	NULL
CD4	NULL
*T	NULL
cells	NULL
,	NULL
NK	NULL
cells	NULL
,	NULL
macrophages	NULL
,	NULL
and	NULL
CD11¢	NULL
'	NULL
DCs	NULL
can	NULL
kill	NULL
some	NULL
tumor	NULL
cells	NULL
via	NULL
TRAIL	NULL
under	NULL
certain	NULL
conditions	NULL
(	NULL
19	NULL
,	NULL
26	NULL
,	NULL
27	NULL
,	NULL
37	NULL
,	NULL
38	NULL
)	NULL
.	NULL

To	NULL
investigate	NULL
whether	NULL
CD34DCs	NULL
or	NULL
MoDCs	NULL
cultured	NULL
in	NULL
vitro	NULL
have	NULL
similar	NULL
cytotoxic	NULL
capacity	NULL
,	NULL
and	NULL
if	NULL
so	NULL
whether	NULL
they	NULL
use	NULL
TRAIL	NULL
to	NULL
perform	NULL
this	NULL
function	NULL
,	NULL
we	NULL
first	NULL
evaluated	NULL
the	NULL
susceptibility	NULL
of	NULL
the	NULL
two	NULL
TRAIL-sensitive	NULL
tumor	NULL
cells	NULL
to	NULL
the	NULL
cytotoxic	NULL
effects	NULL
of	NULL
CD34DCs	NULL
or	NULL
MoDCs	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

3	NULL
A	NULL
,	NULL
unstimulated	NULL
MoDCs	NULL
or	NULL
LPS-stimulated	NULL
MoDC	NULL
's	NULL
did	NULL
not	NULL
have	NULL
obvious	NULL
cytotoxicity	NULL
to	NULL
HL6O	NULL
cells	NULL
at	NULL
the	NULL
E	NULL
:	NULL
T	NULL
ratios	NULL
used	NULL
.	NULL

However	NULL
,	NULL
IFN-B	NULL
could	NULL
markedly	NULL
potentiate	NULL
MoDCs	NULL
to	NULL
kill	NULL
HL60	NULL
cells	NULL
.	NULL

Unstimulated	NULL
and	NULL
LPS-stimulated	NULL
MoDCs	NULL
could	NULL
kill	NULL
Reh	NULL
cells	NULL
only	NULL
at	NULL
a	NULL
high	NULL
E	NULL
:	NULL
T	NULL
ratio	NULL
(	NULL
20:1	NULL
)	NULL
,	NULL
whereas	NULL
IFN-B-stimulated	NULL
MoDCs	NULL
could	NULL
induce	NULL
obvious	NULL
death	NULL
of	NULL
Reh	NULL
cells	NULL
at	NULL
all	NULL
E	NULL
:	NULL
T	NULL
ratios	NULL
(	NULL
Fig	NULL
.	NULL

3B	NULL
)	NULL
.	NULL

Similarly	NULL
,	NULL
only	NULL
after	NULL
IFN-	NULL
$	NULL
stimulation	NULL
could	NULL
CD34DCs	NULL
efficiently	NULL
kill	NULL
HL6O	NULL
cells	NULL
at	NULL
an	NULL
E	NULL
:	NULL
T	NULL
ratio	NULL
of	NULL
20:1	NULL
and	NULL
Reh	NULL
cells	NULL
at	NULL
all	NULL
E	NULL
:	NULL
T	NULL
ratios	NULL
,	NULL
as	NULL
compared	NULL
with	NULL
unstimulated	NULL
and	NULL
LPS-stimulated	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
,	NULL
C	NULL
and	NULL
D	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
IFN-B	NULL
could	NULL
significantly	NULL
enhance	NULL
the	NULL
cytotoxicity	NULL
of	NULL
CD34DCs	NULL
or	NULL
MoDCs	NULL
.	NULL

Having	NULL
ascertained	NULL
that	NULL
IFN-	NULL
$	NULL
B	NULL
can	NULL
up-regulate	NULL
TRAIL	NULL
expression	NULL
on	NULL
DCs	NULL
,	NULL
and	NULL
to	NULL
confirm	NULL
whether	NULL
up-regulation	NULL
of	NULL
TRAIL	NULL
was	NULL
responsible	NULL
for	NULL
the	NULL
enhanced	NULL
cytotoxicity	NULL
of	NULL
CD34DCs	NULL
or	NULL
MoDCs	NULL
60	NULL
©	NULL
3	NULL
E	NULL
-+-	NULL
HL60	NULL
c	NULL
-a-	NULL
U937	NULL
2	NULL
'=	NULL
.	NULL

El	NULL
--	NULL
Daudi	NULL
E	NULL
209	NULL
-m-	NULL
Jurkat	NULL
o	NULL
-x-	NULL
Reh	NULL
E	NULL
C	NULL
N4	NULL
:	NULL
0	NULL
25	NULL
50	NULL
75	NULL
100	NULL
TRAIL	NULL
(	NULL
ng/ml	NULL
)	NULL
FIGURE	NULL
2	NULL
.	NULL

Growth	NULL
inhibition	NULL
of	NULL
tumor	NULL
cells	NULL
of	NULL
hemopoietic	NULL
origin	NULL
by	NULL
TRAIL	NULL
.	NULL

HL60	NULL
,	NULL
Reh	NULL
,	NULL
Jurkat	NULL
,	NULL
Daudi	NULL
,	NULL
and	NULL
U937	NULL
cells	NULL
were	NULL
incubated	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
TRAIL	NULL
at	NULL
the	NULL
indicated	NULL
concentration	NULL
for	NULL
24	NULL
h	NULL
,	NULL
and	NULL
then	NULL
their	NULL
viability	NULL
was	NULL
measured	NULL
by	NULL
MTT	NULL
assay	NULL
.	NULL

Percent	NULL
growth	NULL
inhibition	NULL
was	NULL
quan-titated	NULL
as	NULL
previously	NULL
described	NULL
in	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL

Data	NULL
represent	NULL
one	NULL
consistent	NULL
result	NULL
from	NULL
three	NULL
independent	NULL
experiments	NULL
.	NULL

6107	NULL
'0t	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
[	NULL
810	NULL
fountwrut	NULL
[	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
The	NULL
Journal	NULL
of	NULL
Immunology	NULL
induced	NULL
by	NULL
IFN-B	NULL
stimulation	NULL
,	NULL
we	NULL
pretreated	NULL
IFN-B-stimulated	NULL
CD34DCs	NULL
or	NULL
MoDCs	NULL
with	NULL
TRAIL-R3-Fc	NULL
to	NULL
block	NULL
TRAIL	NULL
.	NULL

We	NULL
then	NULL
observed	NULL
their	NULL
cytotoxicity	NULL
against	NULL
HL6O	NULL
cells	NULL
or	NULL
Reh	NULL
cells	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

4	NULL
,	NULL
A	NULL
and	NULL
B	NULL
,	NULL
TRAIL-R3-Fc	NULL
but	NULL
not	NULL
the	NULL
isotype-matched	NULL
control	NULL
could	NULL
partially	NULL
reduce	NULL
the	NULL
cytotoxicity	NULL
of	NULL
stimulated	NULL
MoDCs	NULL
or	NULL
CD34DCs	NULL
against	NULL
HL6O	NULL
cells	NULL
as	NULL
compared	NULL
with	NULL
the	NULL
control	NULL
(	NULL
p	NULL
<	NULL
0.05	NULL
)	NULL
.	NULL

Similarly	NULL
,	NULL
TRAIL-R3-Fc	NULL
(	NULL
but	NULL
not	NULL
>	NULL
HL60	NULL
-a-	NULL
IFN-beta-MoDC	NULL
Cytotoxicity	NULL
(	NULL
%	NULL
)	NULL
o	NULL
3	NULL
&	NULL
-=-	NULL
LPS-MoDC	NULL
-+-MoDC	NULL
20:1	NULL
10:1	NULL
51	NULL
E/T	NULL
B	NULL
60	NULL
Reh	NULL
£	NULL
3g	NULL
a0	NULL
-+-MoDC	NULL
E	NULL
-=-	NULL
LPS-MoDC	NULL
5	NULL
--	NULL
IFN-beta-MoDC	NULL
&	NULL
20	NULL
P	NULL
O	NULL
0	NULL
20:1	NULL
10:1	NULL
5:1	NULL
E/T	NULL
C	NULL
50	NULL
HL60	NULL
40	NULL
30	NULL
20	NULL
Cytotoxicity	NULL
(	NULL
%	NULL
)	NULL
>	NULL
5	NULL
CD34DC	NULL
LPS-	NULL
IFN-CD34DC	NULL
_	NULL
CD34DC	NULL
x	NULL
30	NULL
Reh	NULL
20	NULL
-	NULL
»	NULL
>	NULL
-CD34DC	NULL
-	NULL
#	NULL
-	NULL
LPS-CD34DC	NULL
--	NULL
IFN-CD3DC	NULL
Cytotoxicity	NULL
(	NULL
%	NULL
)	NULL
o	NULL
5	NULL
to	NULL
o	NULL
I	NULL
10:1	NULL
5	NULL
:	NULL
E/T	NULL
FIGURE	NULL
3	NULL
.	NULL

Cytotoxicity	NULL
of	NULL
DCs	NULL
to	NULL
TRAIL-sensitive	NULL
tumor	NULL
cells	NULL
.	NULL

Human	NULL
MoDCs	NULL
(	NULL
cultured	NULL
for	NULL
5	NULL
days	NULL
)	NULL
or	NULL
CD34DCs	NULL
(	NULL
cultured	NULL
for	NULL
12	NULL
days	NULL
)	NULL
were	NULL
cultured	NULL
with	NULL
IFN-B	NULL
(	NULL
100	NULL
ng/ml	NULL
)	NULL
,	NULL
with	NULL
LPS	NULL
(	NULL
100	NULL
ng/ml	NULL
)	NULL
,	NULL
or	NULL
in	NULL
medium	NULL
alone	NULL
for	NULL
12	NULL
h.	NULL
They	NULL
were	NULL
then	NULL
cocultured	NULL
with	NULL
*'Cr-labeled	NULL
TRAIL-sensitive	NULL
tumor	NULL
cells	NULL
at	NULL
the	NULL
indicated	NULL
E	NULL
:	NULL
T	NULL
ratios	NULL
for	NULL
another	NULL
18	NULL
h.	NULL
The	NULL
cytotoxicity	NULL
of	NULL
DCs	NULL
to	NULL
TRAIL-sensitive	NULL
tumor	NULL
cells	NULL
was	NULL
detected	NULL
using	NULL
the	NULL
'Cr	NULL
release	NULL
assays	NULL
as	NULL
described	NULL
in	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL

A	NULL
,	NULL
Cytotoxicity	NULL
of	NULL
MoDCs	NULL
to	NULL
HL6O	NULL
cells	NULL
;	NULL
B	NULL
,	NULL
cytotoxicity	NULL
of	NULL
MoDCs	NULL
to	NULL
Reh	NULL
cells	NULL
;	NULL
C	NULL
,	NULL
cytotoxicity	NULL
of	NULL
CD34DCs	NULL
to	NULL
HL6O	NULL
cells	NULL
at	NULL
an	NULL
E	NULL
:	NULL
T	NULL
ratio	NULL
of	NULL
20:1	NULL
;	NULL
D	NULL
,	NULL
cytotoxicity	NULL
of	NULL
CD34DCs	NULL
to	NULL
Reh	NULL
cells	NULL
.	NULL

Data	NULL
at	NULL
each	NULL
E	NULL
:	NULL
T	NULL
ratio	NULL
are	NULL
expressed	NULL
as	NULL
mean	NULL
+	NULL
SD	NULL
of	NULL
triplicate	NULL
wells	NULL
.	NULL

Similar	NULL
results	NULL
were	NULL
obtained	NULL
in	NULL
three	NULL
independent	NULL
experiments	NULL
.	NULL

5411	NULL
human	NULL
IgG1	NULL
)	NULL
could	NULL
incompletely	NULL
inhibit	NULL
IFN-B-stimulated	NULL
MoDCs	NULL
or	NULL
CD34DCs	NULL
to	NULL
kill	NULL
Reh	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
,	NULL
C	NULL
and	NULL
1D	NULL
)	NULL
.	NULL

Therefore	NULL
,	NULL
IFN-B-stimulated	NULL
CD34DCs	NULL
or	NULL
MoDCs	NULL
could	NULL
effectively	NULL
kill	NULL
TRAIL-sensitive	NULL
tumor	NULL
cells	NULL
partially	NULL
via	NULL
TRAIL	NULL
.	NULL

60	NULL
HL60	NULL
-+-	NULL
MoDC	NULL
-a-	NULL
MoDC-	NULL
TRAIL-R3	NULL
:	NULL
Fe	NULL
-a-	NULL
MoDC+IgG1	NULL
20	NULL
0	NULL
20:1	NULL
10:1	NULL
5:1	NULL
E/T	NULL
i	NULL
S	NULL
/	NULL
Cytotoxicity	NULL
(	NULL
%	NULL
)	NULL
w	NULL
30	NULL
a	NULL
&	NULL
é	NULL
‘	NULL
20	NULL
-+-E	NULL
-a-	NULL
CD34DC+TRAIL-R3Fe	NULL
€	NULL
.\§\E	NULL
--	NULL
CD34DC+HgG1	NULL
£	NULL
.	NULL

10	NULL
&	NULL
0	NULL
20:1	NULL
10:1	NULL
5:1	NULL
E/T	NULL
C	NULL
30	NULL
Reh	NULL
€	NULL
E	NULL
20	NULL
-+-MoDC	NULL
a	NULL
-a-	NULL
MoDC+TRAIL-R3Fc	NULL
g	NULL
-a-	NULL
MoDC+12G1	NULL
£	NULL
io	NULL
o	NULL
0	NULL
20:1	NULL
10:1	NULL
5:1	NULL
E/T	NULL
D	NULL
30	NULL
-+-	NULL
CD34DC	NULL
to	NULL
&	NULL
Cytotoxicity	NULL
(	NULL
%	NULL
)	NULL
-a-	NULL
CD34DC	NULL
+	NULL
TRAIL-R3	NULL
:	NULL
Fe	NULL
--	NULL
CD34DC+gG1	NULL
o	NULL
20:1	NULL
10:1	NULL
511	NULL
E/T	NULL
FIGURE	NULL
4	NULL
.	NULL

Involvement	NULL
of	NULL
TRAIL	NULL
in	NULL
the	NULL
cytotoxicity	NULL
of	NULL
IFN-B-stimulated	NULL
DCs	NULL
to	NULL
TRAIL-sensitive	NULL
tumor	NULL
cells	NULL
.	NULL

IFN-B-stimulated	NULL
MoDCs	NULL
or	NULL
CD34DCs	NULL
were	NULL
pretreated	NULL
with	NULL
TRAIL-R3-Fc	NULL
(	NULL
1	NULL
pg/ml	NULL
)	NULL
or	NULL
human	NULL
IgG1	NULL
(	NULL
1	NULL
g/mol	NULL
)	NULL
for	NULL
30	NULL
min	NULL
.	NULL

They	NULL
were	NULL
then	NULL
cocultured	NULL
with	NULL
*'Cr-labeled	NULL
TRAIL-sensitive	NULL
tumor	NULL
cells	NULL
for	NULL
another	NULL
18	NULL
h.	NULL
The	NULL
effect	NULL
of	NULL
TRAIL-R3-Fc	NULL
on	NULL
the	NULL
cytotoxicity	NULL
of	NULL
IFN-B-stimulated	NULL
DCs	NULL
to	NULL
TRAIL-sensitive	NULL
tumor	NULL
cells	NULL
was	NULL
detected	NULL
by	NULL
``	NULL
'Cr	NULL
release	NULL
assays	NULL
.	NULL

A	NULL
,	NULL
Cytotoxicity	NULL
of	NULL
IFN-B-stimulated	NULL
MoDCs	NULL
to	NULL
HL6O0	NULL
cells	NULL
;	NULL
B	NULL
,	NULL
cytotoxicity	NULL
of	NULL
CD34DCs	NULL
to	NULL
HL6O	NULL
cells	NULL
;	NULL
C	NULL
,	NULL
cytotoxicity	NULL
of	NULL
IFN-B-stimulated	NULL
MoDCs	NULL
to	NULL
Reh	NULL
cells	NULL
;	NULL
D	NULL
,	NULL
cytotoxicity	NULL
of	NULL
IFN-B-stimulated	NULL
CD34DCs	NULL
to	NULL
Reh	NULL
cells	NULL
.	NULL

Data	NULL
at	NULL
each	NULL
E	NULL
:	NULL
T	NULL
ratio	NULL
are	NULL
shown	NULL
as	NULL
mean	NULL
*	NULL
SD	NULL
of	NULL
triplicate	NULL
wells	NULL
.	NULL

Similar	NULL
results	NULL
were	NULL
obtained	NULL
in	NULL
three	NULL
independent	NULL
experiments	NULL
.	NULL

6107	NULL
'0t	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
[	NULL
810	NULL
fountwrut	NULL
[	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
5412	NULL
CYTOTOXICITY	NULL
OF	NULL
IFN-B-STIMULATED	NULL
HUMAN	NULL
DC	NULL
TO	NULL
TUMOR	NULL
CELLS	NULL
Involvement	NULL
of	NULL
caspase-3	NULL
activation	NULL
in	NULL
the	NULL
sensitivity	NULL
of	NULL
tumor	NULL
cells	NULL
to	NULL
the	NULL
cytotoxicity	NULL
of	NULL
IFN-B-stimulated	NULL
DCs	NULL
Next	NULL
,	NULL
we	NULL
investigated	NULL
the	NULL
intracellular	NULL
mechanism	NULL
of	NULL
the	NULL
cytotoxicity	NULL
of	NULL
IFN-B-stimulated	NULL
DCs	NULL
toward	NULL
tumor	NULL
cells	NULL
.	NULL

Most	NULL
apoptosis-inducing	NULL
ligands	NULL
(	NULL
CD95L	NULL
,	NULL
TRAIL	NULL
,	NULL
TNF-a	NULL
)	NULL
can	NULL
induce	NULL
apoptosis	NULL
through	NULL
activation	NULL
of	NULL
the	NULL
caspase	NULL
cascade	NULL
.	NULL

Caspase-8	NULL
is	NULL
an	NULL
apical	NULL
member	NULL
of	NULL
the	NULL
caspase	NULL
cascade	NULL
,	NULL
the	NULL
activation	NULL
of	NULL
which	NULL
can	NULL
induce	NULL
activation	NULL
of	NULL
downstream	NULL
caspases	NULL
.	NULL

Caspase-3	NULL
activation	NULL
is	NULL
thought	NULL
to	NULL
contribute	NULL
to	NULL
cleavage	NULL
of	NULL
downstream	NULL
substrates	NULL
such	NULL
as	NULL
poly-	NULL
(	NULL
ADP	NULL
lamins	NULL
,	NULL
and	NULL
actins	NULL
,	NULL
leading	NULL
to	NULL
a	NULL
series	NULL
of	NULL
apoptotic	NULL
events	NULL
,	NULL
such	NULL
as	NULL
DNA	NULL
fragmentation	NULL
,	NULL
cellular	NULL
skeleton	NULL
collapse	NULL
,	NULL
etc	NULL
.	NULL

(	NULL
28	NULL
)	NULL
.	NULL

Before	NULL
we	NULL
investigated	NULL
whether	NULL
the	NULL
activation	NULL
of	NULL
caspases	NULL
was	NULL
involved	NULL
in	NULL
the	NULL
killing	NULL
of	NULL
HL6O	NULL
cells	NULL
or	NULL
Reh	NULL
cells	NULL
by	NULL
IFN-B-stimulated	NULL
CD34DCs	NULL
or	NULL
MoDC	NULL
's	NULL
,	NULL
we	NULL
examined	NULL
the	NULL
kinetic	NULL
activation	NULL
of	NULL
caspase-3	NULL
and	NULL
caspase-8	NULL
in	NULL
HL6O0	NULL
cells	NULL
and	NULL
Reh	NULL
cells	NULL
induced	NULL
by	NULL
TRAIL	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

5	NULL
,	NULL
activated	NULL
subunits	NULL
were	NULL
released	NULL
from	NULL
procaspase	NULL
3	NULL
and	NULL
procaspase	NULL
8	NULL
after	NULL
incubating	NULL
for	NULL
2	NULL
h.	NULL
Maximal	NULL
levels	NULL
of	NULL
activated	NULL
subunits	NULL
were	NULL
seen	NULL
after	NULL
6	NULL
h	NULL
and	NULL
were	NULL
maintained	NULL
until	NULL
12	NULL
h	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
TRAIL	NULL
.	NULL

After	NULL
incubation	NULL
with	NULL
TRAIL	NULL
for	NULL
24	NULL
h	NULL
,	NULL
activated	NULL
subunits	NULL
in	NULL
HL6O	NULL
cells	NULL
or	NULL
Reh	NULL
cells	NULL
were	NULL
still	NULL
detectable	NULL
but	NULL
at	NULL
a	NULL
low	NULL
level	NULL
.	NULL

We	NULL
then	NULL
pre-incubated	NULL
HL6O0	NULL
cells	NULL
and	NULL
Reh	NULL
cells	NULL
with	NULL
caspase-3	NULL
inhibitor	NULL
for	NULL
30	NULL
min	NULL
before	NULL
coculture	NULL
with	NULL
IFN-f-stimulated	NULL
CD34DCs	NULL
or	NULL
MoDCs	NULL
and	NULL
observed	NULL
its	NULL
effect	NULL
on	NULL
cytotoxicity	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

6	NULL
,	NULL
A	NULL
and	NULL
B	NULL
,	NULL
the	NULL
sensitivity	NULL
of	NULL
HL60	NULL
cells	NULL
and	NULL
Reh	NULL
cells	NULL
to	NULL
the	NULL
cytotoxicity	NULL
of	NULL
IFN-B-stimulated	NULL
MoDCs	NULL
or	NULL
CD34DCs	NULL
was	NULL
significantly	NULL
reduced	NULL
(	NULL
p	NULL
<	NULL
0.05	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
caspase-3	NULL
activation	NULL
was	NULL
clearly	NULL
involved	NULL
in	NULL
the	NULL
killing	NULL
of	NULL
TRAIL-sensitive	NULL
tumor	NULL
cells	NULL
by	NULL
IFN-B-stimulated	NULL
MoDCs	NULL
or	NULL
CD34DCs	NULL
.	NULL

Involvement	NULL
of	NULL
NF-KB	NULL
activation	NULL
in	NULL
the	NULL
sensitivity	NULL
of	NULL
tumor	NULL
cells	NULL
to	NULL
the	NULL
cytotoxicity	NULL
of	NULL
DCs	NULL
TRAIL	NULL
can	NULL
induce	NULL
not	NULL
only	NULL
the	NULL
activation	NULL
of	NULL
the	NULL
caspase	NULL
cascade	NULL
leading	NULL
to	NULL
apoptotic	NULL
death	NULL
events	NULL
but	NULL
also	NULL
the	NULL
activation	NULL
of	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
pathway	NULL
,	NULL
which	NULL
is	NULL
associated	NULL
with	NULL
the	NULL
resistance	NULL
of	NULL
some	NULL
tumor	NULL
cells	NULL
to	NULL
TRAIL-mediated	NULL
apoptosis	NULL
.	NULL

NF-	NULL
«	NULL
B	NULL
inhibitor	NULL
can	NULL
efficiently	NULL
change	NULL
some	NULL
TRAIL-resistant	NULL
tumor	NULL
cells	NULL
into	NULL
TRAIL-sensitive	NULL
cells	NULL
(	NULL
30	NULL
,	NULL
32	NULL
)	NULL
.	NULL

Because	NULL
CD3A4DCs	NULL
and	NULL
LPS-stimulated	NULL
caspase3p20	NULL
n	NULL
FIGURE	NULL
5	NULL
.	NULL

The	NULL
activation	NULL
of	NULL
caspase-3	NULL
and	NULL
caspase-8	NULL
in	NULL
the	NULL
TRAIL-sensitive	NULL
tumor	NULL
cells	NULL
in	NULL
duced	NULL
by	NULL
TRAIL	NULL
.	NULL

HL60	NULL
cells	NULL
or	NULL
Reh	NULL
cells	NULL
were	NULL
cultured	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
TRAIL	NULL
(	NULL
100	NULL
ng/m	NULL
!	NULL
)	NULL

plus	NULL
TRAIL	NULL
enhancer	NULL
(	NULL
500	NULL
ng/m	NULL
!	NULL
)	NULL

for	NULL
0	NULL
,	NULL
2	NULL
,	NULL
6	NULL
,	NULL
12	NULL
,	NULL
and	NULL
24	NULL
h	NULL
(	NULL
lanes	NULL
1-5	NULL
)	NULL
,	NULL
and	NULL
then	NULL
the	NULL
activated	NULL
sub-	NULL
1	NULL
units	NULL
of	NULL
caspase-3	NULL
or	NULL
caspase-8	NULL
were	NULL
examined	NULL
by	NULL
Western	NULL
blot	NULL
assay	NULL
.	NULL

kd	NULL
,	NULL
Kilodaltons	NULL
.	NULL

«	NULL
ys	NULL
Caspase3p20	NULL
CIG	NULL
snip	NULL
somes	NULL
CD34DCs	NULL
did	NULL
not	NULL
kill	NULL
HL60	NULL
cells	NULL
or	NULL
Reh	NULL
cells	NULL
efficiently	NULL
,	NULL
we	NULL
evaluated	NULL
whether	NULL
they	NULL
could	NULL
induce	NULL
death	NULL
of	NULL
HL60	NULL
cells	NULL
or	NULL
Reh	NULL
cells	NULL
pretreated	NULL
with	NULL
NF-KB	NULL
inhibitor	NULL
.	NULL

In	NULL
this	NULL
case	NULL
,	NULL
CD34DCs	NULL
and	NULL
LPS-stimulated	NULL
CD34DC	NULL
's	NULL
or	NULL
MoDCs	NULL
could	NULL
easily	NULL
kill	NULL
HL6O	NULL
cells	NULL
or	NULL
Reh	NULL
cells	NULL
after	NULL
pretreatment	NULL
with	NULL
NF-	NULL
«	NULL
B	NULL
inhibitor	NULL
as	NULL
compared	NULL
to	NULL
untreated	NULL
groups	NULL
(	NULL
p	NULL
<	NULL
0.05	NULL
)	NULL
.	NULL

(	NULL
Fig	NULL
.	NULL

7	NULL
)	NULL
.	NULL

Therefore	NULL
,	NULL
the	NULL
sensitivity	NULL
of	NULL
tumor	NULL
cells	NULL
to	NULL
the	NULL
cytotoxicity	NULL
of	NULL
DCs	NULL
could	NULL
be	NULL
up-regulated	NULL
by	NULL
inhibition	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
.	NULL

Discussion	NULL
Our	NULL
studies	NULL
show	NULL
that	NULL
CD34DCs	NULL
or	NULL
MoDCs	NULL
stimulated	NULL
by	NULL
IFN-B	NULL
can	NULL
efficiently	NULL
kill	NULL
TRAIL-sensitive	NULL
HL60	NULL
cells	NULL
and	NULL
Reh	NULL
cells	NULL
.	NULL

The	NULL
cytotoxicity	NULL
was	NULL
partially	NULL
related	NULL
to	NULL
the	NULL
up-regulation	NULL
of	NULL
TRAIL	NULL
expression	NULL
on	NULL
the	NULL
DCs	NULL
by	NULL
IFN-	NULL
stimulation	NULL
.	NULL

Both	NULL
caspase	NULL
activation	NULL
and	NULL
NF-KB	NULL
activation	NULL
were	NULL
involved	NULL
in	NULL
the	NULL
control	NULL
of	NULL
the	NULL
sensitivity	NULL
of	NULL
HL6O0	NULL
cells	NULL
and	NULL
Reh	NULL
cells	NULL
to	NULL
IFN-B-stimulated	NULL
DC-mediated	NULL
killing	NULL
.	NULL

The	NULL
tumoricidal	NULL
activity	NULL
of	NULL
DCs	NULL
was	NULL
enhanced	NULL
more	NULL
markedly	NULL
by	NULL
stimulation	NULL
of	NULL
IFN-	NULL
$	NULL
than	NULL
LPS	NULL
,	NULL
which	NULL
was	NULL
partially	NULL
associated	NULL
with	NULL
the	NULL
up-regulation	NULL
of	NULL
TRAIL	NULL
expression	NULL
.	NULL

We	NULL
do	NULL
not	NULL
exclude	NULL
the	NULL
possibility	NULL
that	NULL
other	NULL
mechanisms	NULL
also	NULL
contribute	NULL
to	NULL
the	NULL
antitumor	NULL
effect	NULL
.	NULL

Fas	NULL
ligand	NULL
,	NULL
TNF-	NULL
@	NULL
,	NULL
and	NULL
nitric	NULL
oxide	NULL
expressed	NULL
or	NULL
secreted	NULL
by	NULL
activated	NULL
DCs	NULL
may	NULL
play	NULL
a	NULL
role	NULL
in	NULL
the	NULL
tumoricidal	NULL
activity	NULL
(	NULL
15	NULL
,	NULL
43	NULL
,	NULL
44	NULL
)	NULL
.	NULL

Our	NULL
data	NULL
showing	NULL
that	NULL
TRAIL-R3-Fc	NULL
is	NULL
unable	NULL
to	NULL
completely	NULL
block	NULL
the	NULL
killing	NULL
of	NULL
tumor	NULL
cells	NULL
induced	NULL
by	NULL
DCs	NULL
confirm	NULL
the	NULL
existence	NULL
of	NULL
other	NULL
mechanisms	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
we	NULL
were	NULL
unable	NULL
to	NULL
observe	NULL
whether	NULL
CD34DCs	NULL
or	NULL
MoDCs	NULL
also	NULL
have	NULL
the	NULL
ability	NULL
to	NULL
kill	NULL
TRAIL-resistant	NULL
tumor	NULL
cells	NULL
,	NULL
which	NULL
would	NULL
supply	NULL
more	NULL
convincing	NULL
evidence	NULL
that	NULL
DCs	NULL
use	NULL
TRAIL	NULL
,	NULL
or	NULL
other	NULL
toxic	NULL
molecules	NULL
,	NULL
or	NULL
both	NULL
,	NULL
to	NULL
kill	NULL
tumor	NULL
cells	NULL
.	NULL

The	NULL
study	NULL
of	NULL
Fanger	NULL
et	NULL
al	NULL
.	NULL

revealed	NULL
that	NULL
the	NULL
tumoricidal	NULL
activity	NULL
of	NULL
CD11c	NULL
``	NULL
DCs	NULL
was	NULL
TRAIL	NULL
dependent	NULL
,	NULL
whereas	NULL
that	NULL
of	NULL
Chapoval	NULL
et	NULL
al	NULL
.	NULL

demonstrated	NULL
that	NULL
the	NULL
cytostatic	NULL
effect	NULL
mediated	NULL
by	NULL
MoDCs	NULL
was	NULL
partially	NULL
membrane-bound	NULL
TNF-a	NULL
specific	NULL
(	NULL
18	NULL
,	NULL
19	NULL
)	NULL
.	NULL

IFNs	NULL
were	NULL
discovered	NULL
through	NULL
their	NULL
antiviral	NULL
activity	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
they	NULL
also	NULL
have	NULL
far-ranging	NULL
immunomodulatory	NULL
effects	NULL
on	NULL
several	NULL
kinds	NULL
of	NULL
immune	NULL
cells	NULL
such	NULL
as	NULL
NK	NULL
cells	NULL
,	NULL
T	NULL
cells	NULL
,	NULL
and	NULL
macrophages	NULL
to	NULL
regulate	NULL
host	NULL
defense	NULL
against	NULL
infectious	NULL
agents	NULL
and	NULL
tumor	NULL
3	NULL
4	NULL
5	NULL
102003	NULL
40	NULL
5	NULL
p	NULL
w	NULL
66.2k4	NULL
C	NULL
43.0kd	NULL
$	NULL
4	NULL
ge	NULL
#	NULL
949	NULL
31.0kd	NULL
tuys	NULL
wees	NULL
#	NULL
8	NULL
``	NULL
0	NULL
caspase8p20	NULL
¢	NULL
20.1kd	NULL
Reh-caspase3	NULL
Reh-caspase	NULL
$	NULL
8	NULL
3	NULL
40	NULL
5	NULL
10	NULL
20	NULL
030	NULL
40	NULL
5	NULL
,	NULL
mes	NULL
ma	NULL
*	NULL
~a	NULL
-66.2kd	NULL
r	NULL
-66.2kd	NULL
Nite	NULL
s	NULL
w	NULL
..	NULL
,	NULL
>	NULL
-43.0k4	NULL
|	NULL
_	NULL
oe	NULL
0	NULL
OB	NULL
-	NULL
-43.0kd	NULL
4	NULL
-31.0kd	NULL
-31.0kd	NULL
fies	NULL
d	NULL
--	NULL
-caspase8p20	NULL
I	NULL
h	NULL
@	NULL
--	NULL
20.0kd	NULL
HL6O-caspase3	NULL
HL60-caspase8	NULL
6107	NULL
'0t	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
[	NULL
810	NULL
fountwrut	NULL
[	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
The	NULL
Journal	NULL
of	NULL
Immunology	NULL
cells	NULL
.	NULL

IFNs	NULL
induce	NULL
apoptotic	NULL
cell	NULL
death	NULL
by	NULL
up-regulating	NULL
the	NULL
expression	NULL
of	NULL
a	NULL
variety	NULL
of	NULL
apoptosis-inducing	NULL
molecules	NULL
(	NULL
e.g	NULL
.	NULL

,	NULL
FasL	NULL
,	NULL
TRAIL	NULL
)	NULL
(	NULL
19	NULL
,	NULL
45	NULL
,	NULL
46	NULL
)	NULL
.	NULL

Moreover	NULL
,	NULL
type	NULL
I	NULL
IFNs	NULL
are	NULL
able	NULL
to	NULL
rapidly	NULL
induce	NULL
CD14*	NULL
monocytes	NULL
into	NULL
short-lived	NULL
and	NULL
TRAIL-expressing	NULL
DCs	NULL
with	NULL
potent	NULL
functional	NULL
activities	NULL
(	NULL
47	NULL
)	NULL
.	NULL

These	NULL
previous	NULL
data	NULL
are	NULL
somewhat	NULL
consistent	NULL
with	NULL
our	NULL
results	NULL
,	NULL
where	NULL
we	NULL
have	NULL
shown	NULL
that	NULL
IFN-	NULL
is	NULL
capable	NULL
of	NULL
up-regulating	NULL
TRAIL	NULL
expression	NULL
on	NULL
immature	NULL
CD34DCs	NULL
and	NULL
MoDCs	NULL
.	NULL

There	NULL
has	NULL
been	NULL
no	NULL
relevant	NULL
report	NULL
of	NULL
the	NULL
effect	NULL
of	NULL
IFN-	NULL
on	NULL
DC-mediated	NULL
tumoricidal	NULL
activities	NULL
to	NULL
date	NULL
.	NULL

Our	NULL
study	NULL
is	NULL
the	NULL
first	NULL
to	NULL
report	NULL
that	NULL
IFN-B	NULL
can	NULL
enhance	NULL
DC-mediated	NULL
tumoricidal	NULL
activity	NULL
partially	NULL
via	NULL
up-regulation	NULL
of	NULL
TRAIL	NULL
.	NULL

The	NULL
fact	NULL
that	NULL
type	NULL
I	NULL
IFNs	NULL
stimulate	NULL
DCs	NULL
to	NULL
utilize	NULL
TRAIL	NULL
for	NULL
generating	NULL
apoptotic	NULL
bodies	NULL
might	NULL
enable	NULL
subsequent	NULL
cross-priming	NULL
of	NULL
CD8	NULL
*	NULL
CTLs	NULL
,	NULL
indicating	NULL
that	NULL
type	NULL
I	NULL
IFNs	NULL
may	NULL
be	NULL
powerful	NULL
adjuvants	NULL
to	NULL
bridge	NULL
innate	NULL
and	NULL
adoptive	NULL
immunity	NULL
.	NULL

In	NULL
our	NULL
study	NULL
,	NULL
we	NULL
examined	NULL
the	NULL
killing	NULL
function	NULL
of	NULL
immature	NULL
CD34DCs	NULL
and	NULL
MoDCs	NULL
.	NULL

To	NULL
determine	NULL
whether	NULL
the	NULL
degree	NULL
of	NULL
maturity	NULL
correlates	NULL
with	NULL
cytotoxicity	NULL
,	NULL
we	NULL
analyzed	NULL
the	NULL
cytotoxicity	NULL
of	NULL
mature	NULL
DCs	NULL
induced	NULL
by	NULL
exogenous	NULL
stimuli	NULL
simultaneously	NULL
.	NULL

It	NULL
has	NULL
been	NULL
confirmed	NULL
that	NULL
LPS	NULL
,	NULL
TNF-a	NULL
,	NULL
CD40	NULL
ligand	NULL
,	NULL
and	NULL
IFN-y	NULL
are	NULL
powerful	NULL
maturation	NULL
factors	NULL
that	NULL
induce	NULL
DC	NULL
maturation	NULL
(	NULL
48	NULL
)	NULL
.	NULL

We	NULL
selected	NULL
LPS	NULL
to	NULL
stimulate	NULL
immature	NULL
DCs	NULL
into	NULL
mature	NULL
cells	NULL
.	NULL

After	NULL
12	NULL
h	NULL
incubation	NULL
of	NULL
immature	NULL
CD34DC	NULL
's	NULL
and	NULL
MoDCs	NULL
with	NULL
LPS	NULL
,	NULL
a	NULL
mature	NULL
phenotype	NULL
and	NULL
potent	NULL
functionality	NULL
(	NULL
in	NULL
an	NULL
MLR	NULL
assay	NULL
)	NULL
were	NULL
observed	NULL
,	NULL
which	NULL
suggested	NULL
that	NULL
the	NULL
immature	NULL
DC	NULL
were	NULL
indeed	NULL
induced	NULL
into	NULL
mature	NULL
DCs	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

However	NULL
,	NULL
in	NULL
cytotoxicity	NULL
experiments	NULL
,	NULL
we	NULL
only	NULL
observed	NULL
minimal	NULL
DC-mediated	NULL
tumoricidal	NULL
C	NULL
medium	NULL
alone	NULL
caspase3	NULL
inhibitor	NULL
Cytotoxicity	NULL
(	NULL
%	NULL
)	NULL
W	NULL
,	NULL
MoDC	NULL
:	NULL
HL-60	NULL
MoDC	NULL
:	NULL
Reh	NULL
w	NULL
CJ	NULL
medium	NULL
alone	NULL
caspase3	NULL
inbibitor	NULL
Cytotoxicity	NULL
(	NULL
%	NULL
)	NULL
CD34DC	NULL
:	NULL
Reh	NULL
CD3MMDC	NULL
:	NULL
HLGO	NULL
FIGURE	NULL
6	NULL
.	NULL

Involvement	NULL
of	NULL
caspase-3	NULL
activation	NULL
in	NULL
the	NULL
sensitivity	NULL
of	NULL
tumor	NULL
cells	NULL
to	NULL
the	NULL
cytotoxicity	NULL
of	NULL
IFN-B-stimulated	NULL
DCs	NULL
.	NULL

*'Cr-labeled	NULL
TRAIL-sensitive	NULL
tumor	NULL
cells	NULL
(	NULL
HL6O	NULL
or	NULL
Reh	NULL
cells	NULL
)	NULL
were	NULL
pretreated	NULL
with	NULL
caspase-3	NULL
inhibitor	NULL
(	NULL
50	NULL
M	NULL
)	NULL
for	NULL
30	NULL
min	NULL
and	NULL
then	NULL
cocultured	NULL
with	NULL
IFN-B-stimulated	NULL
DCs	NULL
for	NULL
another	NULL
18	NULL
h.	NULL
The	NULL
effect	NULL
of	NULL
caspase-3	NULL
inhibitor	NULL
on	NULL
the	NULL
susceptibility	NULL
of	NULL
TRAIL-sensitive	NULL
tumor	NULL
cells	NULL
to	NULL
the	NULL
cytotoxicity	NULL
of	NULL
IFN-B-stimulated	NULL
DCs	NULL
at	NULL
an	NULL
E	NULL
:	NULL
T	NULL
ratio	NULL
of	NULL
10:1	NULL
was	NULL
detected	NULL
by	NULL
*°Cr	NULL
release	NULL
assays	NULL
.	NULL

A	NULL
,	NULL
Cytotoxicity	NULL
of	NULL
IFN-B-stimulated	NULL
MoDCs	NULL
to	NULL
TRAIL-sensitive	NULL
tumor	NULL
cells	NULL
pretreated	NULL
with	NULL
caspase-3	NULL
inhibitor	NULL
;	NULL
B	NULL
,	NULL
cytotoxicity	NULL
of	NULL
IFN-B-stimulated	NULL
CD34DCs	NULL
to	NULL
TRAIL-sensitive	NULL
tumor	NULL
cells	NULL
pretreated	NULL
with	NULL
caspase-3	NULL
inhibitor	NULL
.	NULL

Data	NULL
are	NULL
shown	NULL
as	NULL
the	NULL
mean	NULL
+	NULL
SD	NULL
of	NULL
triplicate	NULL
wells	NULL
.	NULL

Similar	NULL
results	NULL
were	NULL
obtained	NULL
in	NULL
three	NULL
independent	NULL
experiments	NULL
.	NULL

5413	NULL
A	NULL
30	NULL
HL60	NULL
&	NULL
A	NULL
2	NULL
20	NULL
é	NULL
g	NULL
7/	NULL
%	NULL
Z	NULL
C	NULL
medium	NULL
alone	NULL
.	NULL

_	NULL
E	NULL
;	NULL
a	NULL
Z	NULL
Z	NULL
Z	NULL
HANF-KappaB	NULL
inhibitor	NULL
B	NULL
40	NULL
Reh	NULL
ﬁg	NULL
Z	NULL
C	NULL
medium	NULL
alone	NULL
g	NULL
)	NULL
g	NULL
H	NULL
NF-KappaB	NULL
inhibitor	NULL
°	NULL
|	NULL
/	NULL
MoDC	NULL
_	NULL
LPS-MoDC	NULL
IFN-beta-	NULL
MoDC	NULL
C	NULL
60	NULL
pa	NULL
€	NULL
,	NULL
40	NULL
3	NULL
?	NULL

F	NULL
C	NULL
medium	NULL
alone	NULL
9	NULL
5	NULL
NF-kappaB	NULL
inhibitor	NULL
€	NULL
20	NULL
s	NULL
d	NULL
&	NULL
0	NULL
CD3M4DC	NULL
-__	NULL
LPS-	NULL
__	NULL
IFN-beta-CD3MDC	NULL
_	NULL
CD3MDC	NULL
D	NULL
<	NULL
&	NULL
>	NULL
.	NULL

bE	NULL
C	NULL
medium	NULL
alone	NULL
S	NULL
€	NULL
,	NULL
NF-kappaB	NULL
inhibitor	NULL
&	NULL
IFN-beta-CD34DC	NULL
CD34DC	NULL
LPS-CD34DC	NULL
FIGURE	NULL
7	NULL
.	NULL

Involvement	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
in	NULL
the	NULL
TRAIL-sensitive	NULL
tumor	NULL
cells	NULL
to	NULL
the	NULL
cytotoxicity	NULL
of	NULL
DCs	NULL
.	NULL

'*Cr-labeled	NULL
TRAIL-sensitive	NULL
tumor	NULL
cells	NULL
were	NULL
pretreated	NULL
with	NULL
NF-	NULL
«	NULL
B	NULL
inhibitor	NULL
(	NULL
15	NULL
M	NULL
)	NULL
for	NULL
30	NULL
min	NULL
,	NULL
and	NULL
then	NULL
cocultured	NULL
with	NULL
stimulated	NULL
or	NULL
unstimulated	NULL
CD34DCs	NULL
or	NULL
MoDCs	NULL
at	NULL
an	NULL
E	NULL
:	NULL
T	NULL
ratio	NULL
of	NULL
10:1	NULL
for	NULL
another	NULL
18	NULL
h.	NULL
The	NULL
effect	NULL
of	NULL
NF-xB	NULL
inhibitor	NULL
on	NULL
the	NULL
cytotoxicity	NULL
of	NULL
stimulated	NULL
or	NULL
unstimulated	NULL
DCs	NULL
to	NULL
TRAIL-sensitive	NULL
tumor	NULL
cells	NULL
was	NULL
detected	NULL
by	NULL
**Cr	NULL
release	NULL
assays	NULL
.	NULL

A	NULL
,	NULL
Cytotoxicity	NULL
of	NULL
stimulated	NULL
or	NULL
unstimulated	NULL
MoDCs	NULL
to	NULL
HL60	NULL
cells	NULL
;	NULL
B	NULL
,	NULL
cytotoxicity	NULL
of	NULL
stimulated	NULL
or	NULL
unstimulated	NULL
MoDCs	NULL
to	NULL
Reh	NULL
cells	NULL
;	NULL
C	NULL
,	NULL
cytotoxicity	NULL
of	NULL
stimulated	NULL
or	NULL
unstimulated	NULL
CD34DCs	NULL
to	NULL
HL-60	NULL
cells	NULL
;	NULL
D	NULL
,	NULL
cytotoxicity	NULL
of	NULL
stimulated	NULL
or	NULL
unstimulated	NULL
CD34DCs	NULL
to	NULL
Reh	NULL
cells	NULL
.	NULL

Data	NULL
are	NULL
expressed	NULL
as	NULL
the	NULL
mean	NULL
+	NULL
SD	NULL
of	NULL
triplicate	NULL
wells	NULL
.	NULL

Similar	NULL
results	NULL
were	NULL
obtained	NULL
in	NULL
three	NULL
independent	NULL
experiments	NULL
.	NULL

6107	NULL
'0t	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
[	NULL
810	NULL
fountwrut	NULL
[	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
5414	NULL
CYTOTOXICITY	NULL
OF	NULL
IFN-B-STIMULATED	NULL
HUMAN	NULL
DC	NULL
TO	NULL
TUMOR	NULL
CELLS	NULL
activity	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
LPS	NULL
compared	NULL
with	NULL
IFN-B	NULL
.	NULL

Thus	NULL
,	NULL
distinct	NULL
effects	NULL
of	NULL
LPS	NULL
and	NULL
IFN-B	NULL
on	NULL
DC	NULL
were	NULL
suggested	NULL
.	NULL

IFN-B	NULL
seems	NULL
to	NULL
enhance	NULL
killing	NULL
function	NULL
,	NULL
which	NULL
allows	NULL
for	NULL
DCs	NULL
to	NULL
be	NULL
innate	NULL
``	NULL
defense	NULL
soldiers	NULL
``	NULL
able	NULL
to	NULL
induce	NULL
apoptosis	NULL
,	NULL
and	NULL
then	NULL
to	NULL
take	NULL
up	NULL
and	NULL
process	NULL
apoptotic	NULL
Ags	NULL
.	NULL

Alternatively	NULL
,	NULL
LPS	NULL
,	NULL
as	NULL
an	NULL
inflammatory	NULL
factor	NULL
,	NULL
helps	NULL
to	NULL
stimulate	NULL
DCs	NULL
into	NULL
maturation	NULL
and	NULL
then	NULL
to	NULL
play	NULL
conventional	NULL
Ag-presenting	NULL
roles	NULL
.	NULL

A	NULL
question	NULL
remains	NULL
that	NULL
we	NULL
were	NULL
unable	NULL
to	NULL
answer	NULL
in	NULL
our	NULL
system	NULL
,	NULL
whether	NULL
the	NULL
cytotoxicity	NULL
of	NULL
IFN-B-stimulated	NULL
DCs	NULL
via	NULL
TRAIL	NULL
was	NULL
due	NULL
to	NULL
soluble	NULL
TRAIL	NULL
either	NULL
secreted	NULL
from	NULL
DCs	NULL
or	NULL
cleaved	NULL
from	NULL
DCs	NULL
by	NULL
protease	NULL
in	NULL
the	NULL
supernatants	NULL
or	NULL
due	NULL
to	NULL
the	NULL
membrane-bound	NULL
TRAIL	NULL
on	NULL
DCs	NULL
.	NULL

One	NULL
report	NULL
has	NULL
shown	NULL
that	NULL
DC-mediated	NULL
inhibition	NULL
of	NULL
growth	NULL
of	NULL
tumors	NULL
requires	NULL
a	NULL
cell-to-cell	NULL
interaction	NULL
through	NULL
the	NULL
use	NULL
of	NULL
a	NULL
Transwell	NULL
cell	NULL
culture	NULL
system	NULL
(	NULL
Millipore	NULL
,	NULL
Bed-ford	NULL
,	NULL
MA	NULL
)	NULL
(	NULL
18	NULL
)	NULL
.	NULL

Caspases	NULL
are	NULL
a	NULL
family	NULL
of	NULL
intracellular	NULL
cysteine	NULL
proteases	NULL
that	NULL
contribute	NULL
to	NULL
apoptosis	NULL
.	NULL

Under	NULL
most	NULL
circumstances	NULL
,	NULL
the	NULL
heterotet-ramer	NULL
complex	NULL
is	NULL
in	NULL
an	NULL
inactive	NULL
form	NULL
but	NULL
can	NULL
be	NULL
cleaved	NULL
to	NULL
release	NULL
activated	NULL
subunits	NULL
of	NULL
~20	NULL
kDa	NULL
.	NULL

The	NULL
mechanisms	NULL
of	NULL
TRAIL-mediated	NULL
apoptosis	NULL
are	NULL
unknown	NULL
.	NULL

At	NULL
least	NULL
two	NULL
pathways	NULL
have	NULL
been	NULL
confirmed	NULL
as	NULL
regulating	NULL
sensitivity	NULL
to	NULL
TRAIL	NULL
.	NULL

One	NULL
pathway	NULL
participates	NULL
in	NULL
an	NULL
apoptotic	NULL
event	NULL
that	NULL
involves	NULL
the	NULL
activation	NULL
of	NULL
FADD-caspase	NULL
cascades	NULL
triggered	NULL
by	NULL
DR4	NULL
or	NULL
DR5	NULL
.	NULL

The	NULL
other	NULL
pathway	NULL
counteracts	NULL
apoptosis	NULL
and	NULL
may	NULL
be	NULL
correlated	NULL
with	NULL
activation	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
by	NULL
DR4	NULL
,	NULL
DR5	NULL
,	NULL
and	NULL
DCR2	NULL
.	NULL

Certain	NULL
molecules	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
control	NULL
cellular	NULL
survival	NULL
or	NULL
death	NULL
.	NULL

Among	NULL
these	NULL
,	NULL
the	NULL
most	NULL
implicated	NULL
is	NULL
c-FLIP	NULL
the	NULL
gene	NULL
of	NULL
which	NULL
is	NULL
homologous	NULL
to	NULL
that	NULL
of	NULL
caspase-8	NULL
.	NULL

c-FLIP	NULL
prevents	NULL
caspase-8	NULL
from	NULL
entering	NULL
the	NULL
death-inducing	NULL
signal	NULL
complex	NULL
by	NULL
binding	NULL
to	NULL
itself	NULL
,	NULL
but	NULL
it	NULL
is	NULL
unable	NULL
to	NULL
perform	NULL
protease	NULL
activity	NULL
,	NULL
thus	NULL
failing	NULL
to	NULL
deliver	NULL
downstream	NULL
death	NULL
signals	NULL
(	NULL
28	NULL
,	NULL
34-36	NULL
)	NULL
.	NULL

The	NULL
high	NULL
levels	NULL
of	NULL
expression	NULL
of	NULL
c-FLIP	NULL
in	NULL
some	NULL
TRAIL-resistant	NULL
tumor	NULL
cells	NULL
and	NULL
normal	NULL
cells	NULL
may	NULL
explain	NULL
their	NULL
TRAIL-resistant	NULL
properties	NULL
.	NULL

In	NULL
summary	NULL
,	NULL
whether	NULL
cells	NULL
are	NULL
sensitive	NULL
to	NULL
TRAIL	NULL
or	NULL
not	NULL
is	NULL
determined	NULL
not	NULL
only	NULL
by	NULL
the	NULL
net	NULL
abundance	NULL
of	NULL
death	NULL
receptors	NULL
vs	NULL
decoy	NULL
receptors	NULL
exposed	NULL
to	NULL
TRAIL	NULL
but	NULL
also	NULL
by	NULL
the	NULL
balance	NULL
of	NULL
intracellular	NULL
apoptotic	NULL
and	NULL
antiapoptotic	NULL
mechanisms	NULL
.	NULL

Our	NULL
studies	NULL
have	NULL
shown	NULL
that	NULL
DC-mediated	NULL
cytotoxicity	NULL
to	NULL
tumor	NULL
cells	NULL
via	NULL
TRAIL	NULL
involves	NULL
the	NULL
activation	NULL
of	NULL
caspase-3	NULL
in	NULL
tumor	NULL
cells	NULL
and	NULL
that	NULL
the	NULL
sensitivity	NULL
of	NULL
tumor	NULL
cells	NULL
to	NULL
DC-mediated	NULL
cytotoxicity	NULL
was	NULL
increased	NULL
by	NULL
inhibition	NULL
of	NULL
NF-KB	NULL
activation	NULL
in	NULL
tumor	NULL
cells	NULL
.	NULL

Therefore	NULL
,	NULL
whether	NULL
tumor	NULL
cells	NULL
in	NULL
vivo	NULL
are	NULL
eliminated	NULL
by	NULL
effector	NULL
arms	NULL
such	NULL
as	NULL
T	NULL
cells	NULL
,	NULL
NK	NULL
cells	NULL
,	NULL
macrophages	NULL
,	NULL
and	NULL
DC	NULL
is	NULL
dependent	NULL
on	NULL
both	NULL
the	NULL
function	NULL
of	NULL
activated	NULL
effector	NULL
cells	NULL
under	NULL
given	NULL
circumstances	NULL
and	NULL
the	NULL
genetic	NULL
properties	NULL
of	NULL
tumor	NULL
cells	NULL
.	NULL

In	NULL
conclusion	NULL
,	NULL
DCs	NULL
were	NULL
effective	NULL
at	NULL
killing	NULL
TRAIL-sensitive	NULL
tumor	NULL
cells	NULL
partially	NULL
via	NULL
TRAIL	NULL
in	NULL
an	NULL
IFN-B-stimulated	NULL
microen-vironment	NULL
.	NULL

To	NULL
date	NULL
,	NULL
both	NULL
type	NULL
I	NULL
and	NULL
type	NULL
II	NULL
IFNs	NULL
have	NULL
been	NULL
confirmed	NULL
as	NULL
enabling	NULL
DCs	NULL
to	NULL
remove	NULL
tumor	NULL
cells	NULL
via	NULL
up-regulation	NULL
of	NULL
TRAIL	NULL
expression	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
type	NULL
II	NULL
DC	NULL
precursors	NULL
(	NULL
pDC2s	NULL
)	NULL
have	NULL
been	NULL
confirmed	NULL
to	NULL
be	NULL
``	NULL
natural	NULL
IFN-producing	NULL
cells	NULL
,	NULL
``	NULL
which	NULL
generate	NULL
200-1000	NULL
times	NULL
more	NULL
IFN	NULL
than	NULL
any	NULL
other	NULL
subset	NULL
of	NULL
PBMC	NULL
on	NULL
pathogenic	NULL
challenge	NULL
(	NULL
49	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
it	NULL
is	NULL
possible	NULL
that	NULL
an	NULL
innate	NULL
antitumor	NULL
mechanism	NULL
mediated	NULL
by	NULL
DCs	NULL
is	NULL
active	NULL
in	NULL
vivo	NULL
.	NULL

DC	NULL
precursors	NULL
may	NULL
be	NULL
stimulated	NULL
to	NULL
secret	NULL
IFNs	NULL
when	NULL
they	NULL
encounter	NULL
spontaneous	NULL
or	NULL
metastatic	NULL
tumor	NULL
cells	NULL
.	NULL

The	NULL
resulting	NULL
IFNs	NULL
may	NULL
trigger	NULL
DCs	NULL
to	NULL
efficiently	NULL
induce	NULL
apoptosis	NULL
of	NULL
tumor	NULL
cells	NULL
for	NULL
subsequent	NULL
uptake	NULL
and	NULL
processing	NULL
of	NULL
apoptotic	NULL
bodies	NULL
and	NULL
presentation	NULL
of	NULL
antigenic	NULL
peptides	NULL
to	NULL
CD8	NULL
*	NULL
CTLs	NULL
.	NULL

The	NULL
mechanism	NULL
may	NULL
also	NULL
be	NULL
extended	NULL
to	NULL
antiviral	NULL
immunity	NULL
,	NULL
rejection	NULL
of	NULL
transplanta-tion	NULL
,	NULL
and	NULL
autoimmunity	NULL
,	NULL
because	NULL
DCs	NULL
could	NULL
induce	NULL
apoptosis	NULL
of	NULL
,	NULL
and	NULL
then	NULL
capture	NULL
apoptotic	NULL
Ags	NULL
from	NULL
,	NULL
infectious	NULL
cells	NULL
,	NULL
allogeneic	NULL
transplants	NULL
,	NULL
or	NULL
even	NULL
self-tissues	NULL
,	NULL
which	NULL
would	NULL
be	NULL
used	NULL
to	NULL
cross	NULL
prime	NULL
CD8	NULL
*	NULL
CTLs	NULL
.	NULL

Thus	NULL
,	NULL
DCs	NULL
may	NULL
be	NULL
viewed	NULL
as	NULL
a	NULL
bridge	NULL
linking	NULL
the	NULL
innate	NULL
and	NULL
the	NULL
adaptive	NULL
immune	NULL
systems	NULL
.	NULL

Acknowledgments	NULL
We	NULL
thank	NULL
the	NULL
Blood	NULL
Bank	NULL
of	NULL
Shanghai	NULL
for	NULL
gifts	NULL
of	NULL
healthy	NULL
whole	NULL
blood	NULL
;	NULL
Changhai	NULL
Hospital	NULL
for	NULL
gifts	NULL
of	NULL
bone	NULL
marrow	NULL
from	NULL
allogeneic	NULL
transplanta-tion	NULL
;	NULL
Dr.	NULL
W.	NULL
Zhang	NULL
,	NULL
Dr.	NULL
X.	NULL
Huang	NULL
,	NULL
Dr.	NULL
Z.	NULL
Yuan	NULL
,	NULL
Dr.	NULL
T.	NULL
Y.	NULL
Chen	NULL
,	NULL
and	NULL
Dr.	NULL
W.	NULL
G.	NULL
Song	NULL
for	NULL
their	NULL
excellent	NULL
technical	NULL
assistance	NULL
and	NULL
discussion	NULL
of	NULL
this	NULL
work	NULL
.	NULL

We	NULL
also	NULL
thank	NULL
Prof.	NULL
Frances	NULL
Gotch	NULL
for	NULL
helpful	NULL
review	NULL
of	NULL
the	NULL
manuscript	NULL
.	NULL

References	NULL
1	NULL
.	NULL

Steinman	NULL
,	NULL
R.	NULL
M.	NULL
1991	NULL
.	NULL

The	NULL
dendritic	NULL
cells	NULL
system	NULL
and	NULL
its	NULL
role	NULL
in	NULL
immunogenicity	NULL
.	NULL

Annu	NULL
.	NULL

Rev	NULL
.	NULL

Immunol	NULL
.	NULL

9:271	NULL
.	NULL

2	NULL
.	NULL

Celluzzi	NULL
,	NULL
C.	NULL
M.	NULL
,	NULL
J.	NULL
I.	NULL
Mayordomo	NULL
,	NULL
W.	NULL
J.	NULL
Storkus	NULL
,	NULL
M.	NULL
T.	NULL
Lotze	NULL
,	NULL
and	NULL
L.	NULL
D.	NULL
Falo	NULL
,	NULL
Jr.	NULL
1996	NULL
.	NULL

Peptide-pulsed	NULL
dendritic	NULL
cells	NULL
induce	NULL
antigen-specific	NULL
CTL-mediated	NULL
protective	NULL
tumor	NULL
immunity	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

183:283	NULL
.	NULL

3	NULL
.	NULL

Paglia	NULL
,	NULL
P.	NULL
,	NULL
C.	NULL
Chiodoni	NULL
,	NULL
M.	NULL
Rodolfo	NULL
,	NULL
and	NULL
M.	NULL
P.	NULL
Colombo	NULL
.	NULL

1996	NULL
.	NULL

Murine	NULL
dendritic	NULL
cells	NULL
loaded	NULL
in	NULL
vitro	NULL
with	NULL
soluble	NULL
protein	NULL
prime	NULL
cytotoxic	NULL
T	NULL
lymphocytes	NULL
against	NULL
tumor	NULL
antigen	NULL
in	NULL
vivo	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

183:317	NULL
.	NULL

4	NULL
.	NULL

Flamand	NULL
,	NULL
V.	NULL
,	NULL
T.	NULL
Sornasse	NULL
,	NULL
K.	NULL
Thiclemans	NULL
,	NULL
C.	NULL
Demanet	NULL
,	NULL
M.	NULL
Bakkus	NULL
,	NULL
H.	NULL
Bazin	NULL
,	NULL
F.	NULL
Tielemans	NULL
,	NULL
O.	NULL
Leo	NULL
,	NULL
J.	NULL
Urbain	NULL
,	NULL
and	NULL
M.	NULL
Moser	NULL
.	NULL

1994	NULL
.	NULL

Murine	NULL
dendritic	NULL
cells	NULL
pulsed	NULL
in	NULL
vitro	NULL
with	NULL
tumor	NULL
antigen	NULL
induce	NULL
tumor	NULL
resistance	NULL
in	NULL
vivo	NULL
.	NULL

Eur	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

24:605	NULL
.	NULL

5	NULL
.	NULL

De	NULL
Veerman	NULL
,	NULL
M.	NULL
,	NULL
C.	NULL
Heirman	NULL
,	NULL
S.	NULL
van	NULL
Meirvenne	NULL
,	NULL
S.	NULL
Devos	NULL
,	NULL
J.	NULL
Corthalo	NULL
,	NULL
M.	NULL
Moser	NULL
,	NULL
and	NULL
K.	NULL
Thiclemans	NULL
.	NULL

1999	NULL
.	NULL

Retrovirally	NULL
transduced	NULL
bone	NULL
marrow-derived	NULL
dendritic	NULL
cells	NULL
require	NULL
CD4	NULL
*	NULL
T	NULL
cell	NULL
help	NULL
to	NULL
elicit	NULL
protective	NULL
and	NULL
therapeutic	NULL
antitumor	NULL
immunity	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

162:144	NULL
.	NULL

6	NULL
.	NULL

Cao	NULL
,	NULL
X.	NULL
,	NULL
W.	NULL
Zhang	NULL
,	NULL
J.	NULL
Wang	NULL
,	NULL
M.	NULL
Zhang	NULL
,	NULL
X.	NULL
Huang	NULL
,	NULL
H.	NULL
Hamada	NULL
,	NULL
and	NULL
W.	NULL
Chen	NULL
.	NULL

1999	NULL
.	NULL

Therapy	NULL
of	NULL
established	NULL
tumour	NULL
with	NULL
a	NULL
hybrid	NULL
cellular	NULL
vaccine	NULL
generated	NULL
by	NULL
using	NULL
granulocyte-macrophage	NULL
colony-stimulating	NULL
factor	NULL
genetically	NULL
modified	NULL
dendritic	NULL
cells	NULL
.	NULL

Immunology	NULL
97:616	NULL
.	NULL

7	NULL
.	NULL

Ashley	NULL
,	NULL
D.	NULL
M.	NULL
,	NULL
B.	NULL
Faiola	NULL
,	NULL
S.	NULL
Nair	NULL
,	NULL
L.	NULL
P.	NULL
Hale	NULL
,	NULL
D.	NULL
D.	NULL
Bigme	NULL
,	NULL
and	NULL
E.	NULL
Gilboa	NULL
.	NULL

1997	NULL
.	NULL

Bone	NULL
marrow-generated	NULL
dendritic	NULL
cells	NULL
pulsed	NULL
with	NULL
tumor	NULL
extracts	NULL
or	NULL
tumor	NULL
RNA	NULL
induce	NULL
antitumor	NULL
immunity	NULL
against	NULL
central	NULL
nervous	NULL
system	NULL
tumors	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

186:1177	NULL
.	NULL

8	NULL
.	NULL

Mayordomo	NULL
,	NULL
J.	NULL
I.	NULL
,	NULL
T.	NULL
Zorina	NULL
,	NULL
W.	NULL
J.	NULL
Storkus	NULL
,	NULL
L.	NULL
Zitvogel	NULL
,	NULL
C.	NULL
Celluzzi	NULL
,	NULL
L.	NULL
D.	NULL
Falo	NULL
,	NULL
C.	NULL
J.	NULL
Melief	NULL
,	NULL
S.	NULL
T.	NULL
IIdstad	NULL
,	NULL
W.	NULL
M.	NULL
Kast	NULL
,	NULL
and	NULL
A	NULL
.	NULL

B.	NULL
Deleo	NULL
.	NULL

1995	NULL
.	NULL

Bone	NULL
marrow-derived	NULL
dendritic	NULL
cells	NULL
pulsed	NULL
with	NULL
synthetic	NULL
tumour	NULL
peptides	NULL
elicit	NULL
protective	NULL
and	NULL
therapeutic	NULL
antitumour	NULL
immunity	NULL
.	NULL

Nat	NULL
.	NULL

Med	NULL
.	NULL

1:1297	NULL
.	NULL

9	NULL
.	NULL

Albert	NULL
,	NULL
M.	NULL
L.	NULL
,	NULL
B.	NULL
Sauter	NULL
,	NULL
and	NULL
N.	NULL
BharDwaj	NULL
.	NULL

1998	NULL
.	NULL

Dendritic	NULL
cells	NULL
acquire	NULL
antigen	NULL
from	NULL
apoptotic	NULL
cells	NULL
and	NULL
induce	NULL
class	NULL
L-restricted	NULL
CTLs	NULL
.	NULL

Nature	NULL
392:86	NULL
.	NULL

10	NULL
.	NULL

Hoffman	NULL
,	NULL
T.	NULL
K.	NULL
,	NULL
N.	NULL
Meidenbauer	NULL
,	NULL
G.	NULL
Dworacki	NULL
,	NULL
H.	NULL
Kanaya	NULL
,	NULL
and	NULL
T.	NULL
L.	NULL
Whiteside	NULL
.	NULL

2000	NULL
.	NULL

Generation	NULL
of	NULL
tumor-specific	NULL
T-lymphocytes	NULL
by	NULL
cross-priming	NULL
with	NULL
human	NULL
dendritic	NULL
cells	NULL
ingesting	NULL
apoptotic	NULL
tumor	NULL
cells	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

60:3542	NULL
.	NULL

11	NULL
.	NULL

Rovere	NULL
,	NULL
P.	NULL
,	NULL
C.	NULL
Vallinoto	NULL
,	NULL
A.	NULL
Bondanza	NULL
,	NULL
M.	NULL
C.	NULL
Crosti	NULL
M.	NULL
Rescigno	NULL
,	NULL
P.	NULL
Ricciardi-Castagnoli	NULL
,	NULL
C.	NULL
Rugarli	NULL
,	NULL
and	NULL
A	NULL
.	NULL

A.	NULL
Manfredi	NULL
.	NULL

1998	NULL
.	NULL

Bystander	NULL
apoptosis	NULL
triggers	NULL
dendritic	NULL
cell	NULL
maturation	NULL
and	NULL
antigen-presenting	NULL
function	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

161:4467	NULL
.	NULL

12	NULL
.	NULL

Albert	NULL
,	NULL
M.	NULL
L.	NULL
,	NULL
S.	NULL
F.	NULL
A.	NULL
Pearce	NULL
,	NULL
L.	NULL
M.	NULL
Francisco	NULL
,	NULL
B.	NULL
Sauter	NULL
,	NULL
P.	NULL
Roy	NULL
,	NULL
R.	NULL
L.	NULL
Silverstein	NULL
,	NULL
and	NULL
N.	NULL
Bhardwaj	NULL
.	NULL

1998	NULL
.	NULL

Immature	NULL
dendritic	NULL
cells	NULL
phagocytose	NULL
apoptotic	NULL
cells	NULL
via	NULL
a	NULL
,	NULL
fB4	NULL
and	NULL
CD36	NULL
,	NULL
and	NULL
cross-present	NULL
antigens	NULL
to	NULL
cytotoxic	NULL
T	NULL
lymphocytes	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

188:1359	NULL
.	NULL

13	NULL
.	NULL

Todryk	NULL
,	NULL
S.	NULL
,	NULL
A	NULL
.	NULL

A.	NULL
Melcher	NULL
,	NULL
N.	NULL
Hardwick	NULL
,	NULL
B.	NULL
Linardakic	NULL
,	NULL
A.	NULL
Bateman	NULL
,	NULL
M.	NULL
P.	NULL
Colombo	NULL
,	NULL
A.	NULL
Stoppacciaro	NULL
,	NULL
and	NULL
R.	NULL
G.	NULL
Vile	NULL
.	NULL

1999	NULL
.	NULL

Heat	NULL
shock	NULL
protein	NULL
70	NULL
induced	NULL
during	NULL
tumor	NULL
cell	NULL
killing	NULL
induces	NULL
Th1	NULL
cytokines	NULL
and	NULL
targets	NULL
immature	NULL
dendritic	NULL
cell	NULL
precursors	NULL
to	NULL
enhance	NULL
antigen	NULL
uptake	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

163:1398	NULL
.	NULL

14	NULL
.	NULL

Sauter	NULL
,	NULL
B.	NULL
,	NULL
M.	NULL
L.	NULL
Albert	NULL
,	NULL
L.	NULL
Francisco	NULL
,	NULL
M.	NULL
Larsson	NULL
,	NULL
S.	NULL
Somersan	NULL
,	NULL
and	NULL
N.	NULL
Bhardwaj	NULL
.	NULL

2000	NULL
.	NULL

Consequences	NULL
of	NULL
cell	NULL
death	NULL
:	NULL
exposure	NULL
to	NULL
necrotic	NULL
tumor	NULL
cells	NULL
,	NULL
but	NULL
not	NULL
primary	NULL
tissue	NULL
cells	NULL
or	NULL
apoptotic	NULL
cells	NULL
,	NULL
induces	NULL
the	NULL
maturation	NULL
of	NULL
immu-nostimulatory	NULL
dendritic	NULL
cells	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

191:423	NULL
.	NULL

15	NULL
.	NULL

Labeur	NULL
,	NULL
M.	NULL
S.	NULL
,	NULL
B.	NULL
Roters	NULL
,	NULL
B.	NULL
Pers	NULL
,	NULL
A.	NULL
Mechling	NULL
,	NULL
T.	NULL
A.	NULL
Luger	NULL
,	NULL
T.	NULL
Schwarz	NULL
,	NULL
and	NULL
S.	NULL
Grabbe	NULL
.	NULL

1999	NULL
.	NULL

Generation	NULL
of	NULL
tumor	NULL
immunity	NULL
by	NULL
bone	NULL
marrow-derived	NULL
dendritic	NULL
cells	NULL
correlates	NULL
with	NULL
dendritic	NULL
cell	NULL
maturation	NULL
stage	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

162:168	NULL
.	NULL

16	NULL
.	NULL

Yang	NULL
,	NULL
S.	NULL
,	NULL
T.	NULL
L.	NULL
Darrow	NULL
,	NULL
C.	NULL
E.	NULL
Vervacrt	NULL
,	NULL
and	NULL
H.	NULL
F.	NULL
Seigler	NULL
.	NULL

1997	NULL
.	NULL

Immunothera-peutic	NULL
potential	NULL
of	NULL
tumor	NULL
antigen-pulsed	NULL
and	NULL
unpulsed	NULL
dendritic	NULL
cells	NULL
generated	NULL
from	NULL
murine	NULL
bone	NULL
marrow	NULL
.	NULL

Cell	NULL
.	NULL

Immunol	NULL
.	NULL

179:84	NULL
.	NULL

17	NULL
.	NULL

Josien	NULL
,	NULL
R.	NULL
,	NULL
M.	NULL
Heslan	NULL
,	NULL
J.	NULL
P.	NULL
Soulillou	NULL
,	NULL
and	NULL
M.	NULL
C.	NULL
Cuturi	NULL
.	NULL

1997	NULL
.	NULL

Rat	NULL
spleen	NULL
dendritic	NULL
cells	NULL
express	NULL
natural	NULL
killer	NULL
cell	NULL
receptor	NULL
protein	NULL
1	NULL
(	NULL
NKR-P1	NULL
)	NULL
and	NULL
have	NULL
cytotoxic	NULL
activity	NULL
to	NULL
select	NULL
targets	NULL
via	NULL
a	NULL
Ca	NULL
``	NULL
-dependent	NULL
mechanism	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

186:467	NULL
.	NULL

18	NULL
.	NULL

Chapoval	NULL
,	NULL
A.	NULL
I.	NULL
,	NULL
K.	NULL
Tamda	NULL
,	NULL
and	NULL
L.	NULL
Chen	NULL
.	NULL

2000	NULL
.	NULL

In	NULL
vitro	NULL
growth	NULL
inhibition	NULL
of	NULL
a	NULL
broad	NULL
spectrum	NULL
of	NULL
tumor	NULL
cell	NULL
lines	NULL
by	NULL
activated	NULL
human	NULL
dendritic	NULL
cells	NULL
.	NULL

Blood	NULL
.	NULL

95:2346	NULL
.	NULL

19	NULL
.	NULL

Fanger	NULL
,	NULL
N.	NULL
A.	NULL
,	NULL
C.	NULL
R.	NULL
Maliszewski	NULL
,	NULL
K.	NULL
Schooley	NULL
,	NULL
and	NULL
T.	NULL
S.	NULL
Griffith	NULL
.	NULL

1999	NULL
.	NULL

Human	NULL
dendritic	NULL
cells	NULL
mediate	NULL
cellular	NULL
apoptosis	NULL
via	NULL
tumor	NULL
necrosis	NULL
factor-related	NULL
apoptosis-inducing	NULL
ligand	NULL
(	NULL
TRAIL	NULL
)	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

190:1155	NULL
.	NULL

20	NULL
.	NULL

Anderson	NULL
,	NULL
D.	NULL
M.	NULL
,	NULL
E.	NULL
Maraskovsky	NULL
,	NULL
W.	NULL
L.	NULL
Billingsley	NULL
,	NULL
W.	NULL
C.	NULL
Douball	NULL
,	NULL
M.	NULL
E.	NULL
Tometsko	NULL
,	NULL
E.	NULL
R.	NULL
Roux	NULL
,	NULL
M.	NULL
C.	NULL
Teepe	NULL
,	NULL
R.	NULL
E.	NULL
DuBose	NULL
,	NULL
D.	NULL
Cosman	NULL
,	NULL
and	NULL
L.	NULL
Galibert	NULL
.	NULL

1997	NULL
.	NULL

A	NULL
homologue	NULL
of	NULL
the	NULL
TNF	NULL
receptor	NULL
and	NULL
its	NULL
ligand	NULL
enhance	NULL
T-cell	NULL
growth	NULL
and	NULL
dendritic	NULL
cell	NULL
function	NULL
.	NULL

Nature	NULL
390:175	NULL
.	NULL

21	NULL
.	NULL

Chinnaiyan	NULL
,	NULL
A.	NULL
M.	NULL
,	NULL
K.	NULL
O'Rourke	NULL
,	NULL
G.	NULL
L.	NULL
Yu	NULL
,	NULL
R.	NULL
H.	NULL
Lyons	NULL
,	NULL
M.	NULL
Garg	NULL
,	NULL
D.	NULL
R.	NULL
Duan	NULL
,	NULL
L.	NULL
Xing	NULL
,	NULL
R.	NULL
Gentz	NULL
,	NULL
J.	NULL
Ni	NULL
,	NULL
and	NULL
V.	NULL
M.	NULL
Dixit	NULL
.	NULL

1996	NULL
.	NULL

Signal	NULL
transduction	NULL
by	NULL
DR3	NULL
,	NULL
a	NULL
6107	NULL
'0t	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
[	NULL
810	NULL
fountwrut	NULL
[	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
The	NULL
Journal	NULL
of	NULL
Immunology	NULL
22	NULL
.	NULL

23	NULL
.	NULL

24	NULL
.	NULL

25	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

28	NULL
.	NULL

29	NULL
.	NULL

30	NULL
.	NULL

31	NULL
.	NULL

32	NULL
.	NULL

33	NULL
.	NULL

34	NULL
.	NULL

35	NULL
.	NULL

36.	NULL
death	NULL
domain-containing	NULL
receptor	NULL
related	NULL
to	NULL
TNFR-1	NULL
and	NULL
CD95	NULL
.	NULL

Science	NULL
274:990	NULL
.	NULL

Ttoh	NULL
,	NULL
N.	NULL
,	NULL
S.	NULL
I	NULL
.	NULL

A.	NULL
Yonebara	NULL
,	NULL
M.	NULL
Yonebara	NULL
,	NULL
S.	NULL
Mizushima	NULL
,	NULL
M.	NULL
Sameshima	NULL
,	NULL
A.	NULL
Hase	NULL
,	NULL
Y.	NULL
Seto	NULL
,	NULL
and	NULL
S.	NULL
Nagata	NULL
.	NULL

1991	NULL
.	NULL

The	NULL
polypeptide	NULL
encoded	NULL
by	NULL
the	NULL
cDNA	NULL
for	NULL
human	NULL
cell	NULL
surface	NULL
antigen	NULL
Fas	NULL
can	NULL
mediate	NULL
apoptosis	NULL
.	NULL

Cell	NULL
66:233	NULL
.	NULL

Screaton	NULL
,	NULL
G.	NULL
R.	NULL
,	NULL
X.	NULL
N.	NULL
Xu	NULL
,	NULL
A.	NULL
L.	NULL
Olsen	NULL
,	NULL
A.	NULL
E.	NULL
Cowper	NULL
,	NULL
R.	NULL
Tan	NULL
,	NULL
A.	NULL
J.	NULL
McMichael	NULL
,	NULL
and	NULL
J.	NULL
I	NULL
.	NULL

Bell	NULL
.	NULL

1997	NULL
.	NULL

LARD	NULL
:	NULL
a	NULL
new	NULL
lymphoid-specific	NULL
death	NULL
domain	NULL
containing	NULL
receptor	NULL
regulated	NULL
by	NULL
alternative	NULL
pre-mRNA	NULL
splicing	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
94:4615	NULL
.	NULL

Tartaglia	NULL
,	NULL
L.	NULL
A.	NULL
,	NULL
T.	NULL
M.	NULL
Ayres	NULL
,	NULL
G.	NULL
H.	NULL
Wong	NULL
,	NULL
and	NULL
D.	NULL
V.	NULL
Goeddel	NULL
.	NULL

1993	NULL
.	NULL

A	NULL
novel	NULL
domain	NULL
within	NULL
the	NULL
55	NULL
kd	NULL
TNF	NULL
receptor	NULL
signals	NULL
cell	NULL
death	NULL
.	NULL

Cell	NULL
74:845	NULL
.	NULL

Pitti	NULL
,	NULL
R.	NULL
M.	NULL
,	NULL
S.	NULL
A.	NULL
Marsters	NULL
,	NULL
S.	NULL
Ruppert	NULL
,	NULL
C.	NULL
J.	NULL
Donahue	NULL
,	NULL
and	NULL
A.	NULL
Moore	NULL
.	NULL

1996	NULL
.	NULL

Induction	NULL
of	NULL
apoptosis	NULL
by	NULL
Apo-2	NULL
ligand	NULL
,	NULL
a	NULL
new	NULL
member	NULL
of	NULL
the	NULL
tumor	NULL
necrosis	NULL
factor	NULL
cytokine	NULL
family	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

271:12687	NULL
.	NULL

Thomas	NULL
W.	NULL
,	NULL
and	NULL
P.	NULL
Hersey	NULL
.	NULL

1998	NULL
.	NULL

TNP-related	NULL
apoptosis-inducing	NULL
ligand	NULL
(	NULL
TRAIL	NULL
)	NULL
induces	NULL
apoptosis	NULL
in	NULL
Fas	NULL
ligand-resistant	NULL
melanoma	NULL
cells	NULL
and	NULL
mediates	NULL
CD4+	NULL
T	NULL
cell	NULL
killing	NULL
of	NULL
target	NULL
cells	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

161:2195	NULL
.	NULL

Jeremias	NULL
,	NULL
I.	NULL
,	NULL
I.	NULL
Herr	NULL
,	NULL
T.	NULL
Bochler	NULL
,	NULL
and	NULL
K.	NULL
M.	NULL
Debatin	NULL
.	NULL

1998	NULL
.	NULL

TRAIL/Apo-2-ligand-induced	NULL
apoptosis	NULL
in	NULL
human	NULL
T	NULL
cells	NULL
.	NULL

Eur	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

28:143	NULL
.	NULL

Schulze-Osthoff	NULL
,	NULL
K.	NULL
,	NULL
D.	NULL
Ferrari	NULL
,	NULL
M.	NULL
Los	NULL
,	NULL
S.	NULL
Wesselborg	NULL
,	NULL
and	NULL
M.	NULL
E.	NULL
Peter	NULL
.	NULL

1998	NULL
.	NULL

Apoptosis	NULL
signaling	NULL
by	NULL
death	NULL
receptors	NULL
.	NULL

Eur	NULL
.	NULL

J.	NULL
Biochem	NULL
.	NULL

254:439	NULL
.	NULL

Pan	NULL
,	NULL
G.	NULL
,	NULL
J.	NULL
Ni	NULL
,	NULL
Y.	NULL
F.	NULL
Wei	NULL
,	NULL
G.	NULL
Yu	NULL
,	NULL
R.	NULL
Gentz	NULL
,	NULL
and	NULL
V.	NULL
M.	NULL
Dixit	NULL
.	NULL

1997	NULL
.	NULL

An	NULL
antagonist	NULL
decoy	NULL
receptor	NULL
and	NULL
a	NULL
death	NULL
domain-containing	NULL
receptor	NULL
for	NULL
TRAIL	NULL
.	NULL

Science	NULL
277:815	NULL
.	NULL

Sheridan	NULL
,	NULL
J.	NULL
P.	NULL
,	NULL
S.	NULL
A.	NULL
Marsters	NULL
,	NULL
R.	NULL
M.	NULL
Pitti	NULL
,	NULL
A.	NULL
Gurney	NULL
,	NULL
M.	NULL
Skubatch	NULL
,	NULL
D.	NULL
Badwin	NULL
,	NULL
L.	NULL
Ramakrishnan	NULL
,	NULL
C.	NULL
L.	NULL
Gray	NULL
,	NULL
K.	NULL
Baker	NULL
,	NULL
W.	NULL
I	NULL
Wood	NULL
,	NULL
et	NULL
al	NULL
.	NULL

1997	NULL
.	NULL

Control	NULL
of	NULL
TRAIL-induced	NULL
apoptosis	NULL
by	NULL
a	NULL
family	NULL
of	NULL
signaling	NULL
and	NULL
decoy	NULL
receptors	NULL
.	NULL

Science	NULL
277:818	NULL
.	NULL

MacFarlane	NULL
,	NULL
M.	NULL
,	NULL
M.	NULL
Ahmadi	NULL
,	NULL
S.	NULL
M.	NULL
Srinivasula	NULL
,	NULL
T.	NULL
Femades-Alnemri	NULL
,	NULL
G.	NULL
M.	NULL
Cohen	NULL
,	NULL
and	NULL
E.	NULL
S.	NULL
Alnemri	NULL
.	NULL

1997	NULL
.	NULL

Identification	NULL
of	NULL
two	NULL
novel	NULL
receptors	NULL
for	NULL
the	NULL
cytotoxic	NULL
ligand	NULL
TRAIL	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

272:25417	NULL
.	NULL

Chaudhary	NULL
,	NULL
P.	NULL
M.	NULL
,	NULL
M.	NULL
Eby	NULL
,	NULL
A.	NULL
Jasmin	NULL
,	NULL
A.	NULL
Bookwalter	NULL
,	NULL
J.	NULL
Murray	NULL
,	NULL
and	NULL
L.	NULL
Hood	NULL
.	NULL

1997	NULL
.	NULL

Death	NULL
receptor	NULL
5	NULL
,	NULL
a	NULL
new	NULL
member	NULL
of	NULL
the	NULL
TNFR	NULL
family	NULL
,	NULL
and	NULL
DR4	NULL
induce	NULL
FADD-dependent	NULL
apoptosis	NULL
and	NULL
activate	NULL
the	NULL
NF-kB	NULL
pathway	NULL
.	NULL

Immunity	NULL
7:821	NULL
.	NULL

Degli-Esposti	NULL
,	NULL
M.	NULL
A.	NULL
,	NULL
W.	NULL
C.	NULL
Dougall	NULL
,	NULL
P.	NULL
J.	NULL
Smolak	NULL
,	NULL
J.	NULL
Y.	NULL
Waugh	NULL
,	NULL
C.	NULL
A.	NULL
Smith	NULL
,	NULL
and	NULL
R.	NULL
G.	NULL
Goodwin	NULL
.	NULL

1997	NULL
.	NULL

The	NULL
novel	NULL
receptor	NULL
TRAIL-R4	NULL
induces	NULL
NF-KB	NULL
and	NULL
protects	NULL
against	NULL
TRAIL-mediated	NULL
apoptosis	NULL
,	NULL
yet	NULL
retains	NULL
an	NULL
incomplete	NULL
death	NULL
domain	NULL
.	NULL

Immunity	NULL
7:813	NULL
.	NULL

Irmler	NULL
,	NULL
M.	NULL
,	NULL
M.	NULL
Thome	NULL
,	NULL
M.	NULL
Hahne	NULL
,	NULL
P.	NULL
Schneider	NULL
,	NULL
K.	NULL
Hofmann	NULL
,	NULL
V.	NULL
Steiner	NULL
,	NULL
J.	NULL
L.	NULL
Bodmer	NULL
,	NULL
M.	NULL
Schroter	NULL
,	NULL
K.	NULL
Burns	NULL
,	NULL
C.	NULL
Mattmann	NULL
,	NULL
et	NULL
al	NULL
.	NULL

1997	NULL
.	NULL

Inhibition	NULL
of	NULL
death	NULL
receptor	NULL
signals	NULL
by	NULL
cellular	NULL
FLIP	NULL
.	NULL

Nature	NULL
388:190	NULL
.	NULL

Griffith	NULL
,	NULL
T.	NULL
S.	NULL
,	NULL
W.	NULL
A.	NULL
Chin	NULL
,	NULL
G.	NULL
C.	NULL
Jackson	NULL
,	NULL
D.	NULL
H.	NULL
Lynch	NULL
,	NULL
and	NULL
M.	NULL
Z.	NULL
Kubin	NULL
.	NULL

1998	NULL
.	NULL

Intracellular	NULL
regulation	NULL
of	NULL
TRAIL-induced	NULL
apoptosis	NULL
in	NULL
human	NULL
melanoma	NULL
cells	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

161:2833	NULL
.	NULL

Zhang	NULL
,	NULL
X.	NULL
,	NULL
A.	NULL
Franco	NULL
,	NULL
K.	NULL
Myers	NULL
,	NULL
C.	NULL
Gray	NULL
,	NULL
T.	NULL
Nguyen	NULL
,	NULL
and	NULL
P.	NULL
Hersey	NULL
.	NULL

1999	NULL
.	NULL

Relation	NULL
of	NULL
INF-related	NULL
apoptosis-induced	NULL
ligand	NULL
(	NULL
TRAIL	NULL
)	NULL
receptor	NULL
and	NULL
FLICE-inhibitory	NULL
protein	NULL
expression	NULL
to	NULL
TRAIL-induced	NULL
apoptosis	NULL
of	NULL
melanoma	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

59:2747	NULL
.	NULL

37	NULL
.	NULL

38	NULL
.	NULL

39	NULL
.	NULL

40	NULL
.	NULL

41	NULL
.	NULL

42	NULL
.	NULL

43	NULL
.	NULL

45	NULL
.	NULL

46	NULL
.	NULL

47	NULL
.	NULL

48	NULL
.	NULL

49	NULL
.	NULL

5415	NULL
Kayagaki	NULL
,	NULL
N.	NULL
,	NULL
N.	NULL
Yamaguchi	NULL
,	NULL
M.	NULL
Nakayama	NULL
,	NULL
K.	NULL
Takeda	NULL
,	NULL
H.	NULL
Akiba	NULL
,	NULL
H.	NULL
Tsutsui	NULL
,	NULL
H.	NULL
Okamura	NULL
,	NULL
K.	NULL
Nakanishi	NULL
,	NULL
K.	NULL
Okumura	NULL
,	NULL
and	NULL
H.	NULL
Yagita	NULL
.	NULL

1999	NULL
.	NULL

Expression	NULL
and	NULL
function	NULL
of	NULL
TNF-related	NULL
apoptosis-inducing	NULL
ligand	NULL
of	NULL
murine	NULL
activated	NULL
NK	NULL
cells	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

163:1909	NULL
.	NULL

Griffth	NULL
,	NULL
T.	NULL
S.	NULL
,	NULL
S.	NULL
R.	NULL
Wiley	NULL
,	NULL
M.	NULL
Z.	NULL
Kubin	NULL
,	NULL
L.	NULL
M.	NULL
Sedger	NULL
,	NULL
C.	NULL
R.	NULL
Maliszewski	NULL
,	NULL
and	NULL
N.	NULL
A.	NULL
Fanger	NULL
.	NULL

1999	NULL
.	NULL

Monocyte-mediated	NULL
tumoricidal	NULL
activity	NULL
via	NULL
the	NULL
tumor	NULL
necrosis	NULL
factor-related	NULL
cytokine	NULL
,	NULL
TRAIL	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

189:1343	NULL
.	NULL

Szabolcs	NULL
,	NULL
P.	NULL
,	NULL
D.	NULL
Avigan	NULL
,	NULL
S.	NULL
Gezelter	NULL
,	NULL
D.	NULL
H.	NULL
Ciocon	NULL
,	NULL
M.	NULL
A.	NULL
S.	NULL
Moore	NULL
,	NULL
R.	NULL
M.	NULL
Steinman	NULL
,	NULL
and	NULL
J.	NULL
W.	NULL
Young	NULL
.	NULL

1996	NULL
.	NULL

Dendritic	NULL
cells	NULL
and	NULL
macrophages	NULL
can	NULL
mature	NULL
independently	NULL
from	NULL
a	NULL
human	NULL
bone	NULL
marrow-derived	NULL
,	NULL
post-colony-forming	NULL
unit	NULL
intermediate	NULL
.	NULL

Blood	NULL
87	NULL
:	NULL
PP4520	NULL
.	NULL

Sallusto	NULL
,	NULL
F.	NULL
,	NULL
and	NULL
A.	NULL
Lanzavecchia	NULL
.	NULL

1994	NULL
.	NULL

Efficient	NULL
presentation	NULL
of	NULL
soluble	NULL
antigen	NULL
by	NULL
cultured	NULL
human	NULL
dendritic	NULL
cells	NULL
is	NULL
maintained	NULL
by	NULL
granulocyte/macrophage	NULL
colony	NULL
stimulating	NULL
factor	NULL
plus	NULL
interleukin	NULL
4	NULL
and	NULL
downregulated	NULL
by	NULL
tumor	NULL
necrosis	NULL
factor-a	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

179:1109	NULL
.	NULL

Cao	NULL
,	NULL
X.	NULL
,	NULL
W.	NULL
Zhang	NULL
,	NULL
L.	NULL
He	NULL
,	NULL
Z.	NULL
Xie	NULL
,	NULL
S.	NULL
Ma	NULL
,	NULL
Q.	NULL
Tao	NULL
,	NULL
Y.	NULL
Yu	NULL
,	NULL
H.	NULL
Hamada	NULL
,	NULL
and	NULL
J.	NULL
Wang	NULL
.	NULL

1998	NULL
.	NULL

Lymphotactin	NULL
gene-modified	NULL
bone	NULL
marrow	NULL
dendritic	NULL
cells	NULL
act	NULL
as	NULL
more	NULL
potent	NULL
adjuvants	NULL
for	NULL
peptide	NULL
delivery	NULL
to	NULL
induce	NULL
specific	NULL
antitumor	NULL
immunity	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

161:6238	NULL
.	NULL

Hanabuchi	NULL
,	NULL
S.	NULL
,	NULL
M.	NULL
Koyanagi	NULL
,	NULL
A.	NULL
Kawasaki	NULL
,	NULL
N.	NULL
Shinohara	NULL
,	NULL
A.	NULL
Matsuzawa	NULL
,	NULL
Y.	NULL
Nishimura	NULL
,	NULL
Y.	NULL
Kobayashi	NULL
,	NULL
S.	NULL
Yonehara	NULL
,	NULL
H.	NULL
Yagita	NULL
,	NULL
and	NULL
K.	NULL
Okumura	NULL
.	NULL

1994	NULL
.	NULL

Fas	NULL
and	NULL
its	NULL
ligand	NULL
in	NULL
a	NULL
general	NULL
mechanism	NULL
of	NULL
T-cell-mediated	NULL
cytotoxicity	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
9:4930	NULL
.	NULL

Suss	NULL
,	NULL
G.	NULL
,	NULL
and	NULL
K.	NULL
Shortman	NULL
.	NULL

1996	NULL
.	NULL

A	NULL
subclass	NULL
of	NULL
dendritic	NULL
cells	NULL
kills	NULL
CD4	NULL
T	NULL
cells	NULL
via	NULL
Fas/Fas-ligand-induced	NULL
apoptosis	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

183:1789.	NULL
.	NULL

Willenborg	NULL
,	NULL
D.	NULL
O.	NULL
,	NULL
S.	NULL
A.	NULL
Fordham	NULL
,	NULL
M.	NULL
A.	NULL
Staykova	NULL
,	NULL
I	NULL
.	NULL

A.	NULL
Ramshaw	NULL
,	NULL
and	NULL
W.	NULL
B.	NULL
Cowden	NULL
.	NULL

1999	NULL
.	NULL

IFN-y	NULL
is	NULL
critical	NULL
to	NULL
the	NULL
control	NULL
of	NULL
murine	NULL
autoimmune	NULL
encephalomyelitis	NULL
and	NULL
regulates	NULL
both	NULL
in	NULL
the	NULL
periphery	NULL
and	NULL
in	NULL
the	NULL
target	NULL
tissue	NULL
:	NULL
a	NULL
possible	NULL
role	NULL
for	NULL
nitric	NULL
oxide	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

163:5278	NULL
.	NULL

Maciejewski	NULL
,	NULL
J.	NULL
,	NULL
C.	NULL
Selleri	NULL
,	NULL
S.	NULL
Anderson	NULL
,	NULL
and	NULL
N.	NULL
S.	NULL
Young	NULL
.	NULL

1995	NULL
.	NULL

Fas	NULL
antigen	NULL
expression	NULL
on	NULL
CD34*	NULL
human	NULL
marrow	NULL
cells	NULL
induced	NULL
by	NULL
interferon-y	NULL
and	NULL
tumor	NULL
necrosis-	NULL
and	NULL
potentiated	NULL
cytokine	NULL
mediated	NULL
hemopoietic	NULL
suppression	NULL
in	NULL
vitro	NULL
.	NULL

Blood	NULL
85:3183	NULL
.	NULL

Sedger	NULL
,	NULL
L.	NULL
M.	NULL
,	NULL
D.	NULL
M.	NULL
Shows	NULL
,	NULL
R.	NULL
A.	NULL
Blanton	NULL
,	NULL
J.	NULL
J.	NULL
Peschon	NULL
,	NULL
R.	NULL
G.	NULL
Goodwin	NULL
,	NULL
D.	NULL
Cosman	NULL
,	NULL
and	NULL
S.	NULL
R.	NULL
Wiley	NULL
.	NULL

1999	NULL
.	NULL

IFN-y	NULL
mediates	NULL
a	NULL
novel	NULL
antiviral	NULL
activity	NULL
through	NULL
dynamic	NULL
modulation	NULL
of	NULL
TRAIL	NULL
and	NULL
TRAIL	NULL
receptor	NULL
expression	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

163:920	NULL
.	NULL

Santini	NULL
,	NULL
S.	NULL
M.	NULL
,	NULL
C.	NULL
Lapenta	NULL
,	NULL
M.	NULL
Logozzi	NULL
,	NULL
S.	NULL
Parlato	NULL
,	NULL
M.	NULL
Spada	NULL
,	NULL
T.	NULL
di	NULL
Pucchio	NULL
,	NULL
and	NULL
F.	NULL
Belardelli	NULL
.	NULL

2000	NULL
.	NULL

Type	NULL
I	NULL
interferon	NULL
as	NULL
a	NULL
powerful	NULL
adjuvant	NULL
for	NULL
monocyte-derived	NULL
dendritic	NULL
cell	NULL
development	NULL
and	NULL
activity	NULL
in	NULL
vitro	NULL
and	NULL
in	NULL
Hu-PBL-SCID	NULL
mice	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

191:1777	NULL
.	NULL

Banchereau	NULL
,	NULL
J.	NULL
,	NULL
F.	NULL
Briere	NULL
,	NULL
C.	NULL
Caux	NULL
,	NULL
J.	NULL
Davoust	NULL
,	NULL
S.	NULL
Levecque	NULL
,	NULL
Y.	NULL
J.	NULL
Liu	NULL
,	NULL
B.	NULL
Pulendran	NULL
,	NULL
and	NULL
K.	NULL
Palucka	NULL
.	NULL

2000	NULL
.	NULL

Immunobiology	NULL
of	NULL
dendritic	NULL
cells	NULL
.	NULL

Annu	NULL
.	NULL

Rev	NULL
.	NULL

Immunol	NULL
.	NULL

18:767	NULL
.	NULL

Siegal	NULL
,	NULL
F.	NULL
P.	NULL
,	NULL
N.	NULL
Kadowaki	NULL
,	NULL
M.	NULL
Shodell	NULL
,	NULL
P.	NULL
A.	NULL
Fitzgerald-Bocarsly	NULL
,	NULL
K.	NULL
Shah	NULL
,	NULL
H.	NULL
Stephen	NULL
,	NULL
S.	NULL
Amtonenko	NULL
,	NULL
and	NULL
Y.	NULL
J.	NULL
Liu	NULL
.	NULL

1999	NULL
.	NULL

The	NULL
nature	NULL
of	NULL
the	NULL
principal	NULL
type	NULL
1	NULL
interferon-producing	NULL
cells	NULL
in	NULL
human	NULL
blood	NULL
.	NULL

Science	NULL
284:183	NULL
.	NULL

6107	NULL
'0t	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
[	NULL
810	NULL
fountwrut	NULL
[	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL

